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ABSTRACT 
 
Liver disease in equids is often difficult to diagnose, as clinical symptoms are vague and do not 
appear until there is a functional loss of approximately 75% of the liver. Metallothionein (MT) is 
a ubiquitously expressed protein with high affinity for binding zinc in the liver. It has been 
implicated in inflammatory and neoplastic processes in various species, but its role has not been 
evaluated in horses.  
 
To properly appreciate the possible implications of MT expression within the liver, it is crucial to 
understand, globally, the types of hepatic lesions to which equids are susceptible. Therefore, the 
first half of this work aimed to describe the histopathologic lesions of the liver from equids of all 
life stages submitted to the Prairie Diagnostic Services Inc. diagnostic laboratory (Saskatoon, 
SK) from 1995 to 2014, inclusive. Statistical analysis showed that the odds of being diagnosed 
with suppurative to mixed hepatitis was greater in juveniles and yearlings (odds ratio (OR) for 
both = 2.9, 95% confidence interval (CI) = 1.45 to 5.62 and 1.17 to 7.00, respectively), compared 
to adults. The odds of being diagnosed with multi-focal random hepatocellular necrosis were 
greater in fetuses and juveniles than in adults (OR = 77.1 and 6.1, CI = 22.6 to 263.2 and 2.1 to 
17.8, respectively). The odds of being diagnosed with portal fibrosis and bile duct proliferation 
was greater in adults than in juveniles (OR = 5.4, 95% CI = 1.2 to 23.6). Neoplasia was 
diagnosed only in adults, and this was statistically significant (chi-square, P = 0.042). 
Additionally, equids such as donkeys, ponies, Miniature Horses as well as Coldbloods had 
significantly increased odds for the presence of hepatocellular vacuolation (OR = 29.5, 15.7, 7.4 
and 7.9, 95% CI = 5.3 to 164.2, 2.7 to 90.8, 1.3 to 4.0, and 1.06 to 58.6 respectively). The odds 
of being diagnosed with suppurative to mixed hepatitis increased by each calendar year (OR = 
1.07, 95% CI = 1.02 to 1.13). 
 
The second half of this work focused on investigating the expression of MT in the equine liver as 
detected by immunohistochemistry. In particular, the relationship between MT expression and 
histopathologic features of liver disease was examined. These histopathologic features included 
hepatic inflammation, fibrosis, and bile duct proliferation. Also, the relationship between MT 
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expression and cellular regeneration, as determined by Ki-67 immunoreactivity, was determined. 
Metallothionein expression within hepatocytes was increased in 73 of 77 (94.8%) cases with 
chronic equine liver lesions. Statistical analysis found that MT expression was significantly 
associated with Ki-67 expression within bile duct epithelium (P = 0.0004, Mann-Whitney U-
test), resident Kupffer cells (P = 0.0045, Mann-Whitney U-test), as well as with the presence of 
lymphocytic foci (P = 0.0017, Mann-Whitney U-test), suggesting that MT may play a role in 
inflammation and the cellular regeneration of bile duct epithelium in horses. 
 
In conclusion, MT is associated with inflammation and cellular regeneration in equine liver 
disease. Additionally, the hepatic lesions described herein from animals from western Canada, 
though regionally specific, are in alignment with what we know about liver disease in equids.  
From these findings, and from what we currently understand about the pathophysiology of 
equine liver disease, there is an excellent opportunity to pursue further research into the 
development of MT-based diagnostics, preventatives, and therapeutics. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Hepatic disease occurs in a multitude of animal species, including humans. It can have 
significant implications for the animal, and mortality from liver disease is a real threat. This 
likely stems from the fact that the liver has important physiological roles that are crucial to the 
overall functioning of the organism. In addition, its unique vascularization from both the 
systemic and portal circulation exposes the liver not only to systemically circulating antigens, but 
also to gastrointestinally-derived micro-organisms, their products, and inflammatory mediators. 
The liver forms the final defense against these disease-causing agents before they enter the 
systemic circulation. The liver is therefore vital as an immune organ and its contribution to the 
inflammatory process results in the production of numerous pro-inflammatory mediators. These 
mediators, however, are also harmful to the cells of the liver itself and are the cause of additional 
damage during disease.  
 
There is very little information about the occurrence of equine liver lesions in western Canada. 
Differences in breed preference, management practices, grazing areas and food supply may result 
in regional differences in the occurrence and distribution of disease entities. Patients with severe 
hepatic fibrosis often have a poorer prognosis as the liver is unable to regenerate adequately. 
Treatment of liver disease in equids is primarily supportive, to aid the liver in regeneration. 
 
Metallothionein (MT) has been a hot topic of research since its discovery in 1957. It is a metallo-
protein and expressed widely in a variety of species. Metallothionein is expressed constitutively 
in many organs and tissue types, especially the liver. Research has focused predominantly on its 
potential as an anti-inflammatory agent, but it has also been shown to be involved in 
hepatocellular regeneration, as well as the regression and resolution of hepatic fibrosis. It has 
been implicated in numerous human tumors, both as a negative and positive prognostic indicator, 
and its expression has been evaluated in small animal mammary and melanotic tumors. Current 
research is focusing on MT as a prognostic marker, especially in human neoplasia, as well as its 
value as a therapeutic agent, for example as a gene therapy.  
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The following thesis aimed to evaluate the role of MT within the current knowledge of equine 
liver disease. Chapter 2 provides a comprehensive literature review, discussing what we 
currently understand about liver disease in general, the potential role of MT within liver disease 
and liver disease in equids. Chapter 3 briefly summarizes the rationale, objectives, and 
hypotheses of this thesis. The main chapters of this thesis (Chapters 4 and 6), were written as 
manuscripts to be submitted for publication, with a short introduction preceding Chapter 6. 
Chapter 4 contains the results of a 20-year retrospective study of submissions containing hepatic 
lesions submitted to Prairie Diagnostic Services, Inc., and includes a comparison of those 
findings to what is currently known about equine liver disease. Chapter 6 focuses on the role of 
MT in chronic hepatic lesions in horses, and its correlation with histopathologic features of liver 
disease, such as inflammation, bile duct proliferation, and fibrosis. Additionally, the relationship 
between MT expression and cellular regeneration within the liver was explored. The final 
chapter contains the summary and conclusions of these studies, in addition to some thoughts on 
possible future endeavors in this exciting field.  
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 The Basic Structure and Functions of the Liver and Its Role in Disease 
 
The liver arises early in embryogenesis from an out-pouching of endoderm that later forms the 
duodenum.60 By adulthood, it is the largest solid organ in the body and weighs approximately 1.5 
kg in humans and represents 2% of adult body weight.24 In horses and other herbivores, the liver 
constitutes roughly 1% of body weight,60 or about 5 kg in an average 500 kg equid.  
 
Histologically, the liver has classically been described as being organized into lobules in which 
hepatocytes (hepatic epithelial cells) are arranged in cords around a central vein (also referred to 
as the terminal hepatic venule). Venous sinusoids are located between hepatic cords. Along the 
periphery of the lobule are portal triads consisting of bile ducts, branches of the hepatic artery 
and portal vein, nerves and lymphatic vessels, within a network of collagenous connective 
tissue.60 The liver has a dual blood supply, receiving 75% to 80% from the gastrointestinal tract 
(portal circulation) and 20% to 25% arterial blood through the hepatic arteries.24 The blood exits 
the liver via the sinusoids and central and hepatic veins to the vena cava.24 The organ is 
surrounded by a fibrous capsule also known as the Capsule of Glisson. 
 
Hepatocytes (hepatic parenchyma) are the most numerous cell type within the liver and occupy 
78% to 80% of the total liver volume.23 Other cell types associated with the parenchyma include 
intra-sinusoidal Kupffer cells, pit cells, sinusoidal endothelial cells and hepatic stellate cells 
within the Space of Disse.309 The sinusoids, which carry portal blood toward the central vein, are 
lined by unique fenestrated endothelial cells arranged in sieve plates and lack a basal 
lamina.256,308 The fenestrae act as a selective sieve, allowing only molecules of certain sizes 
through, and inhibiting the passage of chylomicrons greater than 200 nm to 250 nm.256 Species-
specific differences in the number and diameter of fenestrae have been demonstrated in several 
animals,256 though no data could be found for equids. Additionally, endothelial cells have high 
endocytic activity, acting as a “scavenger” mechanism for waste molecules from the blood.256  
Hepatic stellate cells are mesenchymal cells that can transform from quiescent lipid and vitamin-
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A storing cells to active myofibroblasts through extracellular signals from inflammatory cells, 
including Kupffer cells.283 Pit cells are found within the hepatic sinusoid and are frequently 
found adhered to endothelial cells. These cells have cytotoxic activity and act as liver-specific 
natural killer cells.174 Kupffer cells, which are resident macrophages within the hepatic sinusoids 
and occasionally within the Space of Disse,256 have high phagocytic activity and can modulate 
the immune system through excretion of bioactive factors, including reactive oxygen species, 
inflammatory and growth control mediators.234 The location of Kupffer cells within the sinusoid 
makes them the first cells of the innate immune system to come in contact with gastrointestinal-
derived foreign and noxious material such as infectious agents, their products (including 
lipopolysaccharide, LPS) and other toxic substances.256  
 
In general, the liver serves the following physiologic functions: 
 
The liver plays a central role in carbohydrate and lipid metabolism. It removes ingested 
carbohydrates and triglycerides that arrive from the gastrointestinal tract via the portal 
circulation. Energy is stored in the liver as glycogen or exported to other organs as fatty acids.60 
Glycogen makes up approximately 5% of the wet weight of the liver,293 which would correspond 
to about 250 g in a 500 kg equid.  Energy is generated in the form of adenosine triphosphate 
through glycolysis, and fatty acid oxidation and approximately 28% of the total hepatocyte 
volume is taken up by mitochondria.23 The liver is also the primary site of cholesterol synthesis, 
and degradation.60 Cholesterol synthesis is dependent on the amount of dietary cholesterol 
intake. However, there is variability in the  rate of cholesterol synthesis, as well the hepatic 
contribution thereof, between different species.75 
 
Synthesis of several plasma proteins also occurs within the liver. These proteins include albumin, 
ceruloplasmin, lipoproteins, proteins of the coagulation cascade (factors II, V, VII to XIII), some 
acute phase proteins and those of the complement system.60 Nitrogen metabolism is also 
completed here, with the conversion of toxic ammonia to non-toxic urea which is excreted by the 
kidneys into the urine.60 
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The liver has an important immune function. For example, hepatocytes produce acute phase 
proteins and coagulation factors which are involved in the systemic inflammatory response.60 
Additionally, Kupffer cells and natural killer cells are crucial components of the innate immune 
system and are first in the line of defense against foreign and noxious materials in the liver. 
Kupffer cells are in a prime position to phagocytize pathogens and foreign materials from both 
portal and arterial circulation and, therefore, form a major defense against gastrointestinally-
derived immunogenic materials.78 Phagocytosis of foreign material, including bacterial 
endotoxin,99 results in the release of numerous bioactive compounds involved in the 
inflammatory response.71,172 These include interleukins, interferons, arachidonic acid 
metabolites, leukotrienes, nitric oxide, among others.71,172 Natural killer cells make up 
approximately 20% to 30% of the liver’s resident lymphocytes.79  
 
One of the main functions of the liver is the excretion of bile. Bile is an aqueous solution 
containing cholesterol, bile salts, bilirubin, amino acids, steroids, and enzymes as well as 
vitamins, heavy metals, and toxins.29 Bile is produced by hepatocytes from cholesterol, excreted 
into bile canaliculi (formed by tight junction-sealed apical membranes of adjacent hepatocytes) 
and drains into bile ducts, making the liver an exocrine organ.29 Bile is modified by the bile duct 
epithelium by way of an energy-dependent transport system that creates an osmotic gradient.29 
The principal functions of bile are the excretion of cholesterol and (harmful) lipophilic 
substances, the emulsification of dietary lipids and the absorption of fat-soluble vitamins (A, D, 
E, and K).60  Bile also serves to transport immunoglobulin A to the mucosal surface of the 
gastrointestinal tract.29  
 
The chemical modification of drugs, pollutants, and other potentially harmful molecules for 
removal from the body is an important task of the liver. Enzymes of the smooth endoplasmic 
reticulum within hepatocytes are responsible for the transformation of these molecules into 
metabolites that are more easily excreted, often by making them more water soluble.5,233 The 
modification process starts with cytochrome p450 enzymes in a process known as phase I 
metabolism and is followed by phase II metabolism where conjugates are added through a 
different set of enzymes. Reabsorption of some metabolites from the gastrointestinal tract occurs 
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in a process known as enterohepatic circulation.5  
 
The liver also serves as an endocrine organ, producing insulin-like growth factor-1 and 
angiotensinogen.95 It is also involved in the metabolic transformation of sterol and thyroid 
hormones, for example, the conversion of thyroxine to triiodothyronine or androgens to 
estrogens.9  
 
As with all other organs, the liver can be affected by primary disease. However, because of its 
involvement in numerous processes, as outlined above, and its unique exposure to both the portal 
and systemic circulation, it is also particularly susceptible to secondary disease. Hepatic 
involvement in gastrointestinal tract disease is not uncommon.35 The inflammatory mediators 
that the liver produces are not only crucial in the clearing of bacteria and other immunogenic 
material but can also create hepatic inflammation and damage.312 Despite the myriad of disease-
causing agents and processes, the liver reacts in limited and predictable ways to injury. These 
include inflammation, fibrosis, biliary hyperplasia, and regeneration.60 As such, it is often 
difficult to discern primary versus secondary hepatic disease on histology alone.  
 
2.2 Reaction Patterns of the Liver in Disease 
 
2.2.1 Hepatic inflammation 
Human hepatic diseases in which inflammation is central to the disease process include: 
alcoholic liver disease, nonalcoholic steatohepatitis (progressive form of nonalcoholic fatty liver 
disease),11 ischemia and reperfusion injury, parasitic infection, and viral hepatitis.11,146 
 
Kupffer cells make up nearly 15% of all cells in the liver.28 Kupffer cells are paramount in the 
initiation and progression of the inflammatory response, both locally within the liver and the 
systemic response. The myriad of pro-inflammatory, biologically active products produced by 
activated Kupffer cells is reviewed extensively by Decker.71 The pro-inflammatory mediators 
produced by Kupffer cells may have deleterious effects on normal hepatic constituents and, 
therefore, are important in the development of hepatitis.21 Blockage of Kupffer cell function by 
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gadolinium chloride resulted in a decrease in both hepatocellular necrosis and inflammation after 
(hepatotoxic) cadmium exposure.77,241 Natural killer T cells play a co-stimulatory role, along 
with Kupffer cells, and induce the Type-1 T-helper (cell) response. Later, during chronic 
inflammation, there is a shift to cytokines that induce the Type-2 T-helper (cell).128 Sinusoidal 
endothelial cells, hepatic stellate cells, natural killer cells, and hepatocytes also produce 
inflammatory mediators that coordinate with Kupffer cells to recruit neutrophils.74 
 
The liver is involved in response to sepsis and critical for the clearance of bacteria and toxins 
from the bloodstream.226 In one study, patients with sepsis had liver lesions that included portal 
inflammation, lobular inflammation, centrilobular necrosis, hepatocellular necrosis, cholangitis, 
and steatosis.163 Hepatic dysfunction occurs early in sepsis and includes decreased glucose and 
xenobiotic metabolism, but hepatic lesions may not be apparent at this time. Later in the septic 
process, and as a response to decreased hepatic function, hepatocellular damage, cholestasis and 
suppurative inflammation occur.201 During sepsis, the liver is responsible for several functions 
including production of proinflammatory cytokines, coagulation factors, complement and other 
acute phase proteins.312 Neutrophils are attracted to the liver by the production of chemokines 
secreted by Kupffer cells, and together with platelets, Kupffer cells, sinusoidal endothelial cells, 
and hepatic stellate cells help clear bacteria.310 Some B lymphocytes also display phagocytic 
activity.232 
 
2.2.2 Hepatic fibrosis 
In humans, hepatic fibrosis may develop in response to viral hepatitis, therapeutic agents, alcohol 
abuse, autoimmune disease, non-alcoholic steatohepatitis, or metabolic disease.15 It is considered 
a form of wound healing, whereby the “scar” is characterized by the exuberant accumulation of 
extracellular matrix (ECM). There is a shift in the composition of the ECM during fibrosis, from 
basement membrane matrix to matrix containing dense fibrillar collagen.100  
 
Hepatic fibrosis has traditionally been viewed as an irreversible process, even if the underlying 
cause is removed.101 More recent evidence has demonstrated that fibrosis is reversible, at least in 
part, in some cases. For example, there was a significant reduction in hepatic fibrosis in the 
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majority of patients after alleviation of stenosis of the common bile duct.120 Also, fibrosis can be 
reversed or stabilized in up to 80% of patients with chronic hepatic inflammation.64 The use of 
anti-inflammatory drugs also highlights the importance of inflammation in the development of 
hepatic fibrosis. Reversal or stabilization of hepatic fibrosis is, however, not consistent in every 
case and the mechanisms of this are still being worked out.  
 
Fibrosis occurs after chronic injury to the liver. Initially, acute hepatocellular damage results in 
regeneration of hepatic parenchymal cells. However, during chronic injury, regeneration fails 
and the hepatic parenchyma is substituted with abundant ECM.15 Hepatic stellate cells are 
activated after injury and transform to myofibroblasts that are able to migrate to the area of 
injury and produce large quantities of ECM.181,191 Kupffer cells are one of the major sources of 
transforming growth factor-ß1, which stimulates stellate cells to transform into 
myofibroblasts.161 Myofibroblasts present within the portal area may also contribute to 
production of ECM.156 
 
Reversal of hepatic fibrosis may occur after removal of the insulting agent and has been 
observed in experimental models and human patients.64,136 Collagenolysis occurs by interstitial 
matrix metalloproteinases (MMPs), activated due to the decrease in the expression of tissue 
inhibitor of metalloproteinase-1.136 Furthermore, the remodeling of the ECM may result in 
apoptosis of hepatic stellate cells.136 Alternatively, reversion of hepatic stellate cell activation 
may occur by interleukin-10, which has been shown to down-regulate inflammation and increase 
collagenase activity.279,296 
 
2.2.3 Hepatic regeneration 
The liver is unique in its ability to regenerate. Unlike other organs, two-thirds of the liver can be 
removed without clinical consequences, and it returns to normal mass within the span of a few 
weeks.124 Unfortunately, the liver is unable to regenerate fully after chronic injury, whereby the 
functional hepatic parenchyma is replaced by connective tissue.25 After an injury, hepatocytes 
are the first cell type that enters the cell cycle and undergoes mitosis, followed by the 
proliferation of biliary epithelial cells, hepatic stellate cells, and Kupffer cells.230 However, 
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hypertrophy of hepatocytes occurs before cell division in models after 70% partial hepatectomy 
(PHx). In models of 30% PHx, hepatocytes infrequently enter into mitosis, and organ mass is 
regained predominantly by hypertrophy.196 Biliary hyperplasia (discussed below) through hepatic 
progenitor cells (HPCs), may form an additional line of regeneration. Hepatic progenitor cells 
(previously referred to as oval cells), with proper growth factors produced by activated hepatic 
stellate cells,91 differentiate into basophilic hepatocytes within four to five days.91,92 In one study, 
in patients with severe hepatic impairment, HPCs were activated after 50% loss of 
hepatocytes.151 The HPC is also able to produce α-fetoprotein and albumin, suggesting an 
additional important physiologic function during hepatic dysfunction.92 Angiogenesis is also 
initiated during hepatic regeneration to re-establish the hepatic vasculature.25  
 
Coordination of hepatic regeneration involves numerous growth factors and other metabolic 
networks.25,177 Tumor necrosis factor-α (TNF-α) binds to Kupffer and other non-parenchymal 
cells, which triggers the release of nuclear factor-κB, and interleukin-6 (IL-6).97 Both can act on 
hepatocytes and are key in initiating hepatocellular regeneration through intracellular signaling 
pathways.58,97 In turn, hepatocytes produce signals for other cell types to stimulate mitosis, 
including transforming growth factor-α, fibroblast growth factor-1 and -2, vascular endothelial 
growth factor, granulocyte macrophage colony-stimulating factor, and angiopoietin-1 and -
2.189,190 
 
Hepatic regeneration is impaired by numerous therapeutic agents, including chemotherapeutic 
drugs, statins, ß-blockers, non-steroidal anti-inflammatory drugs, and others.162,243  In addition, 
after PHx in rodents, a period of hypoglycemia occurs, and supplementation of dextrose also 
impairs hepatic regeneration, suggesting that the regenerative response is coupled to the 
metabolic needs of the animal.304 Regeneration ultimately leads to and stops, when there is 100% 
restoration of a species- and age-specific ratio of total body mass.162,210,276 
 
Several animal models have been developed to study hepatic regeneration. Zebrafish are 
becoming more relevant models for developmental biology in general, and have been the focus 
of studies of liver development and disease research.109,305 The most cited model is the rodent 
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model after PHx, in which the large and median lobes of the liver are surgically removed, 
resulting in loss of approximately two-thirds of the liver.105,124,281 Rodent models involving 
chemically-mediated hepatotoxic injury include the use of carbon tetrachloride (CCL4),
135 and D-
galactosamine.170 Hepatic injury caused by acetaminophen has also been studied in rodents.158 
Genetically modified animal models have also been developed in mice,14 and swine.122 The use 
of animal models has significantly furthered our understanding of hepatic regeneration in 
general.  
 
2.2.4 Biliary hyperplasia 
Bile duct proliferation, also referred to as bile duct hyperplasia or ductular reaction, is a reactive 
process that occurs with hepatic exposure to various insults, and is not limited to biliary injury. It 
involves proliferation of biliary epithelial cells and HPCs, and occasionally metaplasia of mature 
hepatocytes.61 In animals, there are three recognized mechanisms for biliary hyperplasia.61 Bile 
duct obstruction leads to a ductular multiplication of biliary epithelial cells within the portal 
stroma, and these small ducts contain no bile.112 Leakage of bile into the surrounding tissue may 
result in recruitment of neutrophils. Chronic fibrosis and eventually cirrhosis will occur if the 
obstruction cannot be relieved.112 In liver diseases in which there is severe damage to mature 
hepatocytes, and especially when they are unable to replicate, ductular reaction involves 
proliferation and differentiation of bi-potent HPCs.61 These cells are located within the canals of 
Hering and are cytokeratin-7 and -9 positive. This corresponds to a biliary phenotype, despite a 
more prominent phenotypic hepatocyte morphology.212 In contrast, mature hepatocytes are 
positive for cytokeratin-8 and -18.93 With ductular reaction, progenitor cells replicate and 
differentiate to form numerous small and tortuous ducts. A final mechanism of ductular reaction 
described is under conditions of hypoxia when mature hepatocytes can undergo metaplasia and 
proliferation with an intermediate phenotype between cholangiocytes, and hepatocytes.73 
Ductular reactions may lead to parenchymal regeneration, fibrosis, and cirrhosis. They may also 
play a role in neoplasia, either through malignant transformation of the HPCs or by contributing 
to the development of a tumor microenvironment.112 
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In rats, bile duct proliferation with HPC proliferation is seen with D-galactosamine and CCl4 
induced hepatic damage.170,253 and experimental fascioliasis.173 Ductular reactions, both of the 
biliary replication and hepatocyte metaplasia variants, have been described in canine liver 
disease, including chronic hepatitis, cirrhosis, and cholangiocarcinoma.131,314 In equines, biliary 
hyperplasia is seen with pyrrolizidine alkaloid toxicosis, aflatoxicosis, and serum hepatitis.61 
There are species-specific differences in the types of biliary reactions. Therefore, discernment is 
required when comparing animal and human disease models.73,112 
 
2.3 Metallothionein 
 
2.3.1 Introduction 
Metallothionein (MT) was first isolated from the equine kidney in 1957 by Margoshes and 
Vallee as a cadmium-binding protein in the renal cortex.180 It was later purified and further 
characterized by Kägi and Vallee in 1960.147 Metallothionein is a ubiquitously expressed, low 
molecular weight (500-1400 Da), cysteine-rich, intracellular protein.180 Because of its unique 
bioinorganic structure and ability to bind metals, it is referred to as a metalloprotein.277 At the 
time of its discovery, MT’s physical and structural characteristics were suggestive of a 
homeostatic biological role, such as catalysis, detoxification, or storage.147 Early research 
focused on the role of MT in heavy metal detoxification, particularly that of cadmium.297 
Research into its potential role has since grown, and a recent PubMed search for 
“metallothionein” resulted in over 12,900 publications, with 207 publications in the first half of 
2017. Research is focused on a wide variety of topics such as physical chemistry, molecular 
biology, and environmental pollution monitoring. Much of the applied medical research has 
involved studies on humans and research animals (predominantly rodents), involving both 
biochemical and genetic studies of its role. MT’s true biological function, however, remains ill-
defined, despite over 50 years of research.214 It has been extensively reviewed in the 
literature.57,69,119,133,134,198,214,239,277,278 
 
Metallothionein is a ubiquitously expressed protein and found in a large diversity of organisms 
including yeast,299 fungi, and plants.246 A review of MT in animals including mammals, 
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vertebrates, nematodes, annelids, mollusks, and arthropods, among others, is provided by Isani 
and Carpene.134 In it, they describe the genetic heterogeneity between MT isoforms of different 
species, and that these differences do not appear to follow an evolutionary trend in that the least 
complex MT isoforms appear in more evolved vertebrates.134 In primitive life forms, MT plays a 
role in the sequestration of toxic environmental metals.57 For example, MT is constitutively 
expressed within the pharynx of  Caenorhabditis elegans and may act to induce MT expression 
within intestinal cells upon heavy metal exposure.125 The potential diversity of the function of 
the MT protein, based on its structure and biochemistry, is limited only by what is asked of it, 
from an evolutionary perspective. Therefore, the “true” function of MT is most likely dependant 
on the particular needs of that organism. It is frequently cited that there is difficulty in finding a 
unified role for MT, due to its specific and variable roles in different life-forms.22,57 
 
There are four major groups of MT isoforms, which are classified based on numerous factors 
such as their molecular weight, the metal which binds, and genetics.278 The major isoforms 
include MT-1 and MT-2, whereas the minor isoforms include MT-3 and MT-4. Metallothionein-
1 and -2 are expressed during all stages of development and in most organs.213 Metallothionein-3 
was first isolated from brain neurons, and functions as a growth inhibitory factor.288 
Metallothionein-3 is also expressed in the male reproductive organs.197 Metallothionein-4 was 
first isolated from differentiating stratified squamous epithelia.229 It is also found in the upper 
gastrointestinal tract where it helps to regulate stomach pH, the sense of taste and texture on the 
tongue, as well as protects against UV damage of the skin.278 
 
In humans, there are at least ten functional MT isoforms, of the four types, encoded by a family 
of 14 genes on chromosome 16.302 In contrast, there are only four MT encoding genes on 
chromosome eight in mice.229 This has implications for gene regulation, and that what we 
discover from mouse models may not apply to other species. 
 
Transcriptional regulation of the MT gene is achieved in a variety of ways. Within the promotor 
are a number of regions responsive to different molecules. Metals, bound to transcription factors, 
bind to specific areas of the promotor known as metal response elements (MRE). For example, 
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activation by zinc of the MRE-binding transcription factor-1 (MTF-1) causes it to bind to 
DNA.69 Free zinc can bind to the MRE via MTF-1, thus increasing MT mRNA.295 
Metallothionein DNA transcription is also regulated by stress, through glucocorticoid response 
elements within the MT gene promotor.153 Hormones and cytokines may act on the promoter 
through intracellular signaling such as protein kinases.69 For example, 1-alpha, 25-dihydroxy 
vitamin-D3 is known to increase the level of MT mRNA in mice when orally administered.149 
Bacterial endotoxin (LPS) is also known to increase MT mRNA, potentially through IL-6 and 
other cytokines in the mouse.70 Additionally, DNA methylation of the promoter region is 
associated with suppression of MT gene expression in neoplastic hepatocytes in rats, and some 
other types of tumors.106 Regulation of MT gene expression is achieved through many signals, 
both endogenous and exogenously produced.  
 
Not only do MT isoforms show tissue specificity, but also specificity in the metals that they bind 
in those tissues. MT is bound predominantly to zinc in the human and equine liver.34,227 
However, it binds cadmium and zinc in nearly equal proportion in the human kidney.227 The 
equine renal cortex has the highest levels of cadmium, in relation to other organs, and MT 
represents 1% to 2% of the total weight of soluble protein in the renal cortex.147  
 
Metallothionein shows a wide variation in expression in different species and tissue types, and 
this concentration may be dependant on the age, diet, and developmental stage of the 
organism.148 For example, human fetuses did not show evidence of MT expression by 
immunohistochemistry (IHC).102 Metallothionein protein synthesis in rat intestinal mucosal cells 
is related to high levels of zinc in the diet.185 In dogs, MT immunoreactivity has been 
demonstrated in glandular epithelia (mammary, uterine, sweat, olfactory, thyroid, and perianal), 
as well as fundic cells of the stomach, intestinal epithelial cells and hair follicle epithelial 
cells.251 In equids, MT has been isolated and sequenced from the liver, kidney and 
intestine.119,159,160 
 
Within the cell, MT is predominantly found in the cytoplasm. However, degradation of hepatic 
MT occurs predominantly within lysosomes, and the release of its bound metal is a prerequisite 
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for this process.50 It has been observed that MT accumulates bound to copper within hepatic 
lysosomes of Bedlington Terriers with inherited copper toxicosis.143 Transient translocation of 
MT into the nucleus has been seen in cells during proliferation and differentiation, and the 
elevated levels of MT in the nucleus may reflect an increase in demand for zinc by 
metalloenzymes and transcription factors, or to protect from DNA damage which may lead to 
apoptosis.47,51,228 
 
2.3.2 Metallothionein and its role in inflammation 
Metallothionein plays a very important role in inflammation and is considered to have anti-
inflammatory properties. Human patients with diseases such as autoimmune or inflammatory 
bowel disease, cholestasis, and lymphoma had markedly increased expression of hepatic MT by 
IHC.6 Bacterial endotoxin (LPS) can rapidly induce the transcription of hepatic MT in mice.70 In 
addition, IL-6, TNF-α, and interferon-γ (IFN-γ) were also able to induce hepatic MT 
transcription, when injected intraperitoneally.70  
 
The relationship of MT with the acute phase response has been investigated, and MT has been 
considered an acute phase protein because of its rapid response to inflammatory stimuli and 
association with other acute phase proteins. A significant relationship between MT and 
fibrinogen levels was found in mice injected with paraquat, menadione, and CCl4 
subcutaneously. Furthermore, this hepatic MT was bound to zinc.194 The relationship between 
zinc levels and acute inflammation is well established. Zinc plays an important role in both the 
innate and adaptive immune system.26,247 Hypozincemia has been seen during episodes of acute 
stress, such as during sepsis in which patients also have increased markers of oxidative stress and 
inflammatory biomarkers.188 However, hypozincemia is associated with concomitant increases in 
hepatic zinc levels.269 Hepatic levels of zinc increased in mice following LPS exposure, 259,269  
but this accumulation did not occur in MT knock-out mice.224  In addition, it is known that MT 
can sequester zinc in the liver during the acute stage of infection.260 
 
The liver is a major contributor of inflammatory cytokines during systemic inflammation. The 
liver itself is susceptible to cytokine-induced pro-inflammatory injury, and this has been 
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investigated in a mouse model of thermal skin injury.18,45,267 Metallothionein-I and MT-II mRNA 
and intranuclear protein levels were elevated after burn injury when compared to MT-knockout 
mice. Concurrently, increased levels of zinc, copper, and iron were also noted.49 This suggests a 
role of MT in the pathogenesis of hepatic damage during the systemic inflammatory response. 
With regard to other organs, MT knockout mice were more susceptible to lung inflammation 
than wild-type (WT) mice when challenged with intratracheal LPS. Histologically, MT knockout 
mice showed degeneration of type I pneumocytes and endothelial cells, whereas the WT mice 
did not.271  
 
2.3.3 Metallothionein and its role in fibrosis and biliary hyperplasia 
The most recent research on MT has focused on the use of MT gene therapy. Hepatic fibrosis 
induced by CCl4 was reversed in mice with the adenoviral delivery of the MT-2 gene.
140 
Increased levels of MT were associated with increased collagenase activity, and there was 
increased hepatocyte regeneration after gene therapy.140  Furthermore, MT-2 gene therapy was 
able to reverse the phenotype of activated hepatic stellate cells in vitro, thereby reducing the 
mRNA and protein levels of smooth muscle actin and collagen-1 from these cells.311 In dogs 
with chronic hepatitis, MT expression was negatively correlated with the amount of fibrosis.262 
However, no such correlation was found in equids with chronic hepatic disease (refer to Chapter 
4), suggesting a very species-specific mechanism for the potential anti-fibrotic activity of MT.  
 
Matrix metalloproteases are important in the degradation of the ECM and for the reversal of 
hepatic fibrosis, as described earlier. Matrix metalloproteases are a family of endopeptidases and 
are dependent on zinc for their activity.82,113,154 Is it plausible that MT plays a role in fibrinolysis 
and resolution of hepatic fibrosis? Indeed, treatment with luteolin in a CCl4 mouse model of 
hepatic fibrosis resulted in the concomitant increase of MT-1 and MT-2 and MMP-9.81 
Furthermore, supplementation with zinc reduced liver fibrosis in mice as levels of MMP-13 and 
collagenase activity increased.250 
 
There is no established relationship within the liver between MT and biliary hyperplasia. In one 
study by Schmitz et al., MT overexpression was associated with poor patient outcome in cases of 
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cholangiosarcoma.245 Metallothionein within bile duct epithelium in normal livers was 
occasionally only weakly expressed.245  
 
2.3.4 Metallothionein in hepatic regeneration and neoplasia 
Metallothionein expression has been positively correlated with hepatic regeneration (growth 
fraction) in dogs with chronic hepatitis.262 In fetal and newborn rats, MT-1 and MT-2 are found 
in both the nucleus and the cytoplasm, which suggests a role for MT during phases of rapid 
growth.43 Intranuclear localization of MT has also been observed in several human tumors, with 
more intense IHC staining of MT at the proliferating edge of malignant tumors.46 In PHx rats, 
MT is highly expressed within the nucleus and is translocated from the cytoplasm rapidly after 
hepatectomy.281,285 In addition, intra-nuclear staining of MT in hepatocytes was also shown 
within the S and G2/M phases of the cell cycle but intra-cytoplasmic staining occurred most 
prominently within the cytoplasm during G0 and G1 phases.
202,284,285 
 
In mice after PHx, the MT-1 and MT-2 knockout mice have significantly less hepatic 
proliferation than WT mice, suggesting an important role for MT in hepatic regeneration.208 It is 
believed that MT functions as a storage pool and chaperone molecule for zinc, which is required 
by proliferating cells for transcription factors, growth factors, and metalloenzymes.38,289,315  
 
2.3.5 Metallothionein expression as prognostic tool and the therapeutic potential of 
metallothionein 
Metallothionein has been investigated as a potential biomarker in various neoplasms. 
Metallothionein expression has been evaluated in a variety of cancers such as breast 
cancer,16,20,141,244 ovarian cancer,268 renal cell carcinoma,195 acute lymphoblastic leukemia,242 
lung carcinomas,88 colorectal cancer,205 pancreatic carcinoma,206 and melanoma,111,238,266,300 
among others. In many instances, overexpression of MT is considered of prognostic value, as 
higher levels of MT within tumor cells was associated with increased risk for progression, and 
reduced patient survival in melanoma and cholangiosarcoma patients.245,300 However, a recent 
meta-analysis of MT as an IHC biomarker showed a significantly elevated MT expression in 
(human) tumors of the head and neck (tissues of the oral cavity and tongue, pharynx, and larynx) 
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as well as in ovarian tumors, but a decreased MT expression in hepatocellular tumors. 
Furthermore, a significant positive relationship was found between MT expression and tumor 
grade and patient survival.6 Within veterinary research, MT has been investigated in both 
mammary and melanoma neoplasms of dogs and cats. Although no prognostic implication was 
found in this study, it highlighted the species specificity in MT expression within neoplastic 
lesions.76 
 
Interestingly, carcinogenesis and metastasis are also often correlated with an excess of metals 
such as copper and iron.98 Tumor growth, angiogenesis and metastasis have been correlated to 
excess copper.30,115 In turn, copper chelation was shown to inhibit copper-induced migration of 
neoplastic cells in prostate cancer.217 Zinc chelation has been demonstrated to disrupt the 
conformation of the tumor suppressor protein p53 and was thereby able to modulate 
transcriptional activity.187 Metallothionein, which binds heavy metals in the liver may, therefore, 
act as a source of cancer-promoting copper or zinc. 
 
Although hepatic fibrosis is considered a reversible process, current therapeutic regimens against 
hepatic fibrosis have not provided a complete and consistent response, and therefore this is 
currently a “hot topic” of liver disease research.64,301 The most recent research on MT has 
focused on identifying molecular targets,261 as well as the use of MT gene therapy, 140,311  and 
other potential therapeutics, 80,81 for the reversal of hepatic fibrosis.  
 
Of course, one must be judicious in interpreting results from mouse and in vitro models and 
applying them to human subjects. Although the liver has a limited number of reaction patterns, 
for example fibrosis, the etiologies and pathways to obtain that reaction pattern may be 
numerous and diverse. If one considers the number and type of immune cells and their 
inflammatory mediators, it would be foolish to consider all types of liver disease to be the same. 
By manipulating the expression levels of MT in the tissues of patients, we may be exposing them 
to increased risk of neoplasia. 
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2.4 Equine Liver Disease 
 
2.4.1 Hepatic disease in the adult equid 
In general, primary hepatic disease in adult equids is not common but may result in mortality in 
up to 25% cases.87 In one study evaluating the cause of death of 241 mature horses, hepatic 
disease was only found in six horses.192 Because of the liver’s large reserve capacity, signs of 
hepatic disease may not become apparent until there is a loss of greater than 75% of liver 
tissue.275 Very little information is available on the prevalence of hepatic disease in horses, 
except a few reviews out of the western United States,116,192,216 and the United 
Kingdom.83,86,184,303 Most of these reviews focus on the clinicopathologic correlation of hepatic 
disease with clinical signs, histopathology, or survival times, but do not relate findings to 
possible etiologies. 
 
Hepatic disease in equids may result in transient or subclinical liver dysfunction or may cause 
more severe illness or death. Disease may follow an acute or chronic time course or may 
progress as a combination of the two, whereby an acute-on-chronic process may occur. 
 
Primary bacterial hepatitis is rare in mature equids and is most often secondary to gastrointestinal 
disease. The bacteria are thought to ascend the bile ducts and gain access to the liver, resulting in 
a suppurative cholangiohepatitis.222 Horses with proximal enteritis had significantly increased 
serum hepatic enzyme activity, suggestive of hepatic damage.67,290 A recent case of necrotizing 
hepatitis, or black disease, caused by Clostridium novyi was described in a 20-year-old pony in 
western Canada.66 
 
There are several other important causes of hepatic disease in adult equids. This includes 
lipidosis, especially in ponies, donkeys, and Miniature Horses.104,130,139,199,200 Cholelithiasis with 
suppurative cholangiohepatitis has also been described.144 Serum sickness, also known as 
Theiler’s disease, is most likely caused by a Flavivirus, known as Theiler’s Disease Associated 
virus.44 Hepatic lesions involve acute hepatic necrosis and hepatitis, and the loss of hepatocytes 
may be so severe that the liver appears markedly reduced in size.265 Infrequent causes of hepatic 
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disease include abscessation and iron toxicity.209 
 
The nature of the grazing animal puts equids at risk for pasture and feed contaminated toxicities. 
Liver damage may result from the ingestion of pyrrolizidine alkaloid toxin containing plants,3,186 
alsike clover,203 and aflatoxins.36,63,292  
 
Granulomatous and eosinophilic lesions in the liver are most often a result of parasitic larval 
migration of Strongylus vulgaris, Strongylus equinus, Strongylus edentatus, Parascaris equorum 
and Habronema sp..183,263,286 Multi-systemic eosinophilic disease (MEED) has infrequently been 
reported in the literature, but may be a cause of eosinophilic granulomatous lesions in the equine 
liver.41 
 
2.4.2 Hepatic disease in the juvenile equid 
Clostridium piliforme is an important cause of hepatitis and death in foals less than 30 days of 
age.270 The bacterium was first described by E. E. Tyzzer in a colony of waltzing mice in 
1917.287 Pathogenesis of the disease is due to the ingestion of the bacterium in fecal matter from 
adult horses, and its subsequent overgrowth in the nutrient rich intestine of foals.270 
 
Toxic hepatopathy, described as massive necrosis and lobular collapse with mild portal fibrosis, 
has also been described in neonatal foals after administration of a nutritional paste containing 
Aspergillus sp. and an iron compound.2  
 
Genetic diseases that can cause hepatic lesions are rare. However, a retrospective study from 
Berne, Switzerland, identified 30 Swiss Freiberger foals with hepatic disease consistent with 
congenital hepatic fibrosis, which is a genetically inherited disease in other species.117 
 
Septicemia may cause secondary lesions of multi-focal hepatocellular necrosis in the liver. Foal 
septicemia is an important cause of illness in young animals and mortality may reach 75%.164 E. 
coli is frequently cultured (blood culture) in septicemic foal cases.164 Infection was the leading 
cause of morbidity in the first year of life for Thoroughbreds in Ireland, and septicemia was 
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diagnosed in 5.9% of foals, all occurring between 1 and 35 days of age.103 Unfortunately, there 
are no specific symptoms for septicemia, and clinical signs of liver disease often do not 
accompany the clinical disease.164  
 
2.4.3 Hepatic disease in the equine fetus 
Few etiologic agents or disease processes cause significant hepatic pathology in the fetal liver. 
Equid herpes virus-1, and less frequently -4 (EHV-1 and -4), are causes of fetal abortion, often 
despite vaccination of the mare.108,127,178,179,306 Equid herpes virus-1 was the leading cause in 
21.3% of 103 cases of reproductive loss (abortion, stillbirth and early neonatal loss) in a study 
from central Italy,178 8.9% of 290 cases from Michigan,273 and 6.5% of 1252 cases in a study 
from the United Kingdom,108 and 3.3% of 1211 cases from a study out of Kentucky, USA.127 
Occasionally, there is co-infection of EHV-1 with significant bacterial isolates such as Klebsiella 
pneumoniae (lungs), or Actinobacillus equuli (septicemia).179   
 
Hepatic lesions may be seen histologically in other disease processes.  Equine viral arteritis 
predominantly causes lesions in the mare, but when present in the fetus, lesions include 
perivascular lymphocytic infiltrates or severe vasculitis involving the liver, spleen, lung, brain, 
and allantochorion.72,142 Infectious agents responsible for placentitis may gain access to the fetal 
fluids or organs, which can result in hepatic lesions such as hepatocellular degeneration and 
necrosis.306 Leptospirosis, most frequently due to serovars kennewicki or bratislava, is an 
important cause of fetal loss and will often result in gross and microscopic lesions in the 
fetus.90,108,108,306 Hepatic lesions in the fetus include portal lymphocytic and histiocytic infiltrates 
with giant cells within the hepatic parenchyma.306   
 
2.4.4 Neoplastic disease in equids 
Neoplastic disease of the liver is uncommon in equids. While aged equids are susceptible to 
neoplastic lesions, and neoplasia resulted in the death or euthanasia of 18.7% of 241 equids in 
one study, no hepatic neoplastic disease was found.192 Primary liver tumors described in older 
horses include cholangiocarcinoma,84,254 a mixed hepatocellular carcinoma and 
cholangiocarcinoma,150 and a single case of hepatic biliary adenofibroma (a variant of hepatic 
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biliary cystadenoma).240 However, tumors metastatic to the liver are more common than primary 
hepatic neoplasms.59 Multicentric hemangiosarcoma,96 metastatic renal carcinoma,157 and 
multicentric lymphoma85 have all been described in the equine liver. In a retrospective study of 
92 horses in the western United States performed by Hackett et al., five cases of hepatic 
neoplasia were identified and included two cases of lymphosarcoma, an undifferentiated 
neuroendocrine carcinoma, one metastatic thyroid carcinoma, and one leukemia with neoplastic 
lymphoid infiltrates within the hepatic sinusoids.116 
 
Primary hepatic neoplasia is even rarer in young animals. In equids, hepatoblastoma is one of the 
more frequently occurring neoplasms in fetuses and foals and has been described several times in 
the literature.17,39,110,171,225,294 Hepatoblastoma is also one of the more common pediatric tumors 
in humans and accounts for 91% of primary hepatic tumors in children less than five years of 
age.65 Other tumors described in equids include mixed hamartoma237 and mesenchymal 
hamartoma32 in fetuses and hepatocellular carcinoma in foals and young equids.17,138,236  
 
2.5 Copper and Zinc in the Equine Liver 
 
Copper and zinc play vital roles in the structure and function of the mammalian organism. 
Copper is essential for the functioning of enzymes,121 as a structural component of tissues, and as 
an antioxidant and oxidant.211 Similarly, zinc is important in enzyme function, immune 
function,247 and for DNA and protein synthesis.176  In humans, over 10% of the proteome codes 
for zinc-containing enzymes.7   
Equids appear to be relatively resistant to toxicities caused by excessive dietary copper,257 unlike 
what is observed in dogs,94,255 sheep,123 or other ruminants such as goats.55 However, 
musculoskeletal deformities in foals and young horses have been attributed to copper 
deficiencies or with elevated zinc concentrations,31,37,40,89,165 though copper has not been 
implicated in the pathogenesis of osteochondrosis dissecans.298  
 
The main source of zinc and copper is diet, but the absorption of copper may be hindered by 
elevated concentrations of zinc.152 There is a positive correlation between dietary copper intake 
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and hepatic copper concentrations in horses.219 There appears to be no relationship between 
plasma and hepatic copper concentrations or plasma levels and dietary intake in equids.62  
Therefore, determination of the hepatic copper concentration is a better representation of copper 
metabolism, than plasma concentrations.220 In contrast, mean hepatic zinc concentrations did not 
differ among a group of horses fed diets with varying amounts of zinc.62 
 
A recent study (2014) by Paßlack et al.,218 determined the naturally occurring heavy metal 
concentrations of copper, zinc, and cadmium, among others, of 21 horses in Germany.  They 
found that both copper and zinc were higher, and in almost equal proportions, in the liver and 
renal cortex compared to the renal medulla. Cadmium was the highest within the renal cortex, 
followed by renal medulla and liver. No gender differences were found in the amounts of copper 
and zinc in both the liver and kidney. Copper concentrations in the liver were highest in young 
horses less than one year of age. In general, however, there was considerable individual variation 
in heavy metal concentration among horses.  
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CHAPTER 3: RATIONALE AND HYPOTHESES 
 
3.1 Rationale  
Metallothionein (MT) is a ubiquitously expressed metallo-protein found in a wide array of 
species and tissue types. Its expression is induced by various hepatotoxic insults, stressors and 
disease states. It has been shown to play an important role in inflammation, cellular regeneration, 
hepatic fibrosis, and neoplasia. However, even though it has been studied extensively in human 
medicine and rodent models of disease, there are species-specific differences in MT expression 
in health and disease. Hepatic disease in animals and humans often has a poor patient outcome, 
as the liver serves a multitude of functions that are critical to the life of the organism as a whole. 
The liver’s involvement in inflammation is a double-edged sword, as the numerous pro-
inflammatory mediators it can generate also are responsible for much of the damage caused by 
disease. As such, the inciting cause of the liver damage is rarely determined. Therefore, the 
current study aims to elucidate the role of MT in chronic hepatic lesions in horses, independent 
of the etiology, as well as increase our general understanding of histopathologic lesions and their 
potential etiologies in the equine liver.  
 
3.2 Hypothesis 1 
Hepatic histopathologic lesion characteristics and distribution within the local study population 
share similarities to what is currently known about hepatic disease in equids. 
 
3.2.1 Objective 1 
The objective of the first study is to evaluate, by way of retrospective analysis, lesions of liver 
disease in equids submitted to Prairie Diagnostic Services, Inc., from 1995 to 2014, inclusive, 
and to evaluate if the lesions are significantly associated with characteristics such as breed, sex, 
and life stage (fetus, juvenile, yearling, adult) in addition to submission year, season and 
collection method (biopsy, portion, whole-animal necropsy), and to compare the results with 
what is currently known about equine liver disease from the literature. 
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3.3 Hypothesis 2 
Metallothionein is involved in the defense mechanisms against chronic hepatic lesions in equids. 
 
3.3.1 Objective 2 
The objective of the second study is to evaluate the hepatic defense mechanism mediated by MT 
in horses affected by chronic hepatic lesions by examining the correlation between hepatic MT 
expression level and the degree of hepatic inflammation, fibrosis, bile duct proliferation and 
cellular regeneration. 
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4.1 Abstract 
 
Knowledge about hepatic disease in equids is limited to a few retrospective analyses from the 
United Kingdom and the United States focusing predominantly on the clinicopathologic 
correlates of liver disease. This retrospective study was undertaken to describe histopathologic 
lesions of the liver from equids of all life stages, including aborted fetuses, submitted to the 
Prairie Diagnostics Services, Inc. laboratory in Saskatoon, SK from 1995 to 2014, inclusive. 
Furthermore, this study examined whether horse characteristics such as breed, sex and life stage 
(fetus, juvenile, yearling, adult), in addition to submission year, season and collection method 
(biopsy, portion, or whole animal necropsy), were significant characteristics for lesion diagnosis. 
Two hundred fifty-one equids, including ten donkeys, with hepatic lesions, were identified and 
the hematoxylin and eosin stained slides were reviewed. The median age of equids was six years 
old, and sex was evenly distributed. Quarter Horses were the most represented breed in this 
study, followed by Thoroughbreds. Overall, the most commonly diagnosed hepatic lesions were: 
suppurative to mixed hepatitis (88/251, 35.1%), multi-focal hepatocellular necrosis (36/251, 
14.3%), and portal fibrosis with bile duct proliferation (32/251, 12.8%). Life stage was 
consistently statistically associated with several lesion diagnoses (suppurative to mixed hepatitis, 
multi-focal hepatocellular necrosis, portal fibrosis and bile duct proliferation and hepatic 
neoplasia), whereas sex, season and collection method were not. Breed was significantly 
associated with only one lesion diagnosis, hepatocellular vacuolation. Furthermore, a significant 
year to year increase in the number of submissions receiving a diagnosis of suppurative to mixed 
hepatitis was found in the evaluation period.  
 
Key Words: equine, liver, biopsy, hepatitis, abortion, neoplasia. 
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4.2 Introduction 
 
Liver disease is observed in equids and affects all breeds, ages, and genders.41 Signs of hepatic 
disease are often nonspecific, making diagnosis a challenge,11 and diagnosis relies primarily on 
clinicopathologic information such as serum biochemistry and biopsy.3 The value of biopsy as a 
diagnostic tool is heavily dependent on the distribution of the disease process, as equine liver 
biopsy is routinely performed from the 13th intercostal space on the right side.19 An ultrasound-
guided biopsy is an option in those facilities with the equipment, yet even in cases of 
hepatopathy, up to 67% did not show ultrasonographic evidence of hepatic abnormalities.86 
Survival time has been demonstrated to be negatively associated with a high degree of 
neutrophilic inflammation, irreversible cytopathology or other chronic changes in biopsy 
samples,87 suggesting that prognosis is dependent on lesion severity.  
 
Liver disease in horses has a number of causes and may involve transient impairment of liver 
function or may lead to more severe illness or death. Reports on mortality vary but can reach up 
to 80% in affected animals.116 Some of the more serious causes of liver disease in equids include, 
but are not limited to, serum hepatitis,235 Clostridium piliforme (Tyzzer's disease),221 lipidosis,130 
and cholelithiasis126. As horses are grazers, they are also naturally susceptible to liver damage 
caused by ingesting toxic plants such as those containing pyrrolizidine alkaloid toxins,275 alsike 
clover,203 and feed contaminated with mycotoxins.63 Because of this, there may be regional 
differences in the type and frequency of liver lesions to which equids are susceptible. 
 
Reproductive loss is a common problem and occurs in approximately 10% to 15% of pregnant 
mares.306 The majority of abortions arise as embryonal loss early in pregnancy, with one peak of 
fetal loss at around 40 days of gestation and a second peak occurring in the final months of 
gestation.306 Many of the infectious and toxic agents that can cause abortion may also result in 
lesions within the fetal liver. Some agents, such as equid herpesvirus-1 (EHV-1), target the liver 
specifically. Fetal sepsis is most often caused by bacterial agents and results in hepatic lesions 
early in the septic process.312 Therefore, histopathologic evaluation of the fetal liver is a vital 
step in diagnosing the cause of abortion.  
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Few retrospective analyses on equine liver disease exist, the majority of these focus on clinical 
signs, serum biochemistry, and other clinicopathologic correlates.83,86,184,216,303 Of those, the 
largest study included a group of 116 horses with naturally occurring disease in the United 
Kingdom.86  Recent work by Hackett et. al.,116 reviewed histopathology of 92 cases of hepatic 
disease in adult horses in the western United States. However, their study focused primarily on 
histopathologic lesions in relation to patient outcome and clinicopathologic data but did not 
discuss potential etiologies of those lesions. In addition, there are no published studies available 
that have evaluated the type and frequency of hepatic lesions in fetuses and juvenile equids.  
 
The objectives of this study were to describe and characterize the variety of histopathologic 
lesions in the equine liver from western Canada submitted to Prairie Diagnostic Services, Inc. 
(PDS), a diagnostic laboratory in Saskatoon, Canada. The second objective was to investigate if 
individual horse characteristics (life stage, breed, sex), temporal factors (season, year of 
submission) and collection method (biopsy, portion or whole animal necropsy) were significant 
characteristics for lesion diagnosis in this local population. The final objective was to discuss 
potential etiologies, concurrent pathology, and ancillary testing when available and where 
appropriate.  
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4.3 Materials and Methods 
 
4.3.1 Case selection 
The records from submissions received by PDS between January 1, 1995 and December 31, 
2014, were identified by a computer-assisted search and evaluated for histologic evidence of 
hepatic disease (search terms: liver, hepatic, hepatitis, necrotizing, necrosis, inflammation, 
fibrosis, bile duct proliferation, hemorrhage, lipidosis, cirrhosis, inclusion body, neutrophil, 
lymphocyte, and plasma cell). Submissions originated predominantly from the Canadian 
provinces of Saskatchewan and Alberta, although submissions from Manitoba and British 
Columbia were also included. Only those cases with histologic descriptions of the liver lesions 
were assessed, from both horses and donkeys. Hepatic histopathologic lesions from the 
pathology report were confirmed by reviewing the available hematoxylin and eosin (H&E) 
stained liver sections (JNCV and ANA). Reports with similar lesions were first grouped; then 
any statistical or ancillary analysis was performed. 
 
Breed, sex, the age of the animal and collection method (biopsy, portions or full-body necropsy) 
were extracted from the record. If the sex or breed were unknown, or not evident from the 
record, the animal was recorded as “unknown.” If age was not specified, it was left blank. Very 
few individuals represented some breeds. Therefore, breeds were grouped into similar breed 
groups. “Quarter Horse” included similar breeds such as Appaloosas, American Paints, and 
Pintos. Chuckwagon ponies were placed together with Thoroughbreds. Breeds were further 
grouped as “Hotbloods” (Thoroughbred, Arabian, and Morgan), “Warmbloods” (Quarter Horse, 
Belgian Warmblood, Foreign Warmblood), “Coldbloods” (Percherons and Clydesdales), 
“Ponies” (all animals designated as pony, Welsh Pony, or Shetland Pony), donkeys (donkey and 
Miniature Donkey). All cross- and mixed-breeds, two Standardbreds, one Saddle Horse, one 
Icelandic Horse and one Tennessee Walking Horse, were placed in the same category with the 
unknown breeds, to improve statistical power. This “unknown” group became the reference 
group for statistical analysis. Life stage was determined based on the indicated age of the animal, 
or estimated from information from the submitted history or necropsy report if age was not 
specified. An adult horse was any animal over the age of 24 months, a yearling was 10 to 24 
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months (inclusive), and a juvenile (foal) was from birth to 9 months. Gestational age was 
extracted from pathology reports when available or extrapolated and estimated according to 
Kirkbride's Diagnosis of Abortion and Neonatal Loss306 using fetal weight, crown-rump length, 
and other fetal and placental characteristics found in the report. From the date of the pathology 
report, year and season of submission were determined. "Spring" was defined as the months of 
March, April, and May, "summer" as the months of June, July and August, "fall" was defined as 
September, October, and November, and "winter" was defined as December, January, and 
February.  
 
4.3.2 Statistical analysis 
All statistics were performed using Stata 14.2 (StataCorp, College Station, Texas, USA) (JNCV 
and SP). The mean and standard deviation was reported as a measure of central tendency if age 
or fetal age followed a normal distribution. For lesions where age did not follow a normal 
distribution, the median and interquartile range (IQR) were reported. Univariate analysis was 
carried out for each lesion and was conducted using chi-square analysis. Each lesion was 
evaluated to determine if the characteristics (breed, life stage, sex, year of lesion diagnosis and 
season) were significantly associated with the occurrence of that lesion in comparison to all other 
lesion groups. Multi-variate analysis was further performed if potential significant characteristics 
were identified by univariate analysis and were included in the initial model at a relaxed level of 
significance (P ≤ 0.2). The final model building included a more restrictive level of significance 
(P ≤ 0.05). The odds ratio was calculated to compare the differences between groups of a single 
characteristic variable. Evaluation of model fit was performed by evaluating the Pearson 
goodness of fit test and examining the residuals for leverage. The likelihood ratio test was 
performed to compare full and reduced models to test for significant predictors.  
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4.4 Results 
 
Two hundred fifty-one submissions of horses and donkeys with histopathologic hepatic lesions 
were identified. The range of submissions per year was 7 to 20, with 1995 having the lowest 
number of submissions and 2005 the highest (Figure 5-1). The mean number of submissions per 
year was 12.6 (sd = 3.12), and the median was 12.5. The winter season had the lowest number of 
submissions (54/251, 21.5%) compared to spring (65/251, 25.9%), summer (64/251, 25.5%) and 
fall (68/251, 27.1%). Only 32 of 251 (12.8%) submissions were collected by biopsy, with the 
remainder as (organ) portion submissions (78/251, 31.2%) and full-animal necropsies (141/251, 
56%). 
 
The life stage breakdown of the 251 animals included 152 (60.6%) adults, 24 (9.6%) yearlings, 
50 (20.0%) juveniles, and 25 (10.0%) fetuses. The age range was 1 month to 31 years with a 
median of 6 years and IQR of 1 to 13 years. Twenty-four animals were specified only as adults, 
and six animals were determined to be juveniles. Fetal age was estimated in 12 cases, with a 
range of 180 days to 330 days gestation and a mean of 257.5 days (sd = 54.6 days). Thirteen 
fetuses did not have a gestational age estimation. Overall, there were 114 (45.4%) males, 119 
(47.4%) females and 18 (7.2%) were of unknown sex. The breakdown of sex by life-stage is 
given in Table 5-1.  
 
The specified breeds of the 251 equids are given in Table 5-2. Quarter Horses and related breeds 
were the most numerous known breeds represented (96/251, 38.3%), followed by Thoroughbreds 
(27/251, 10.8%) and other Hotbloods (Arabian, Morgan; 15/251, 6.0%).  
 
Table 5-3 lists the frequency and percent proportion by life-stage of hepatic lesions in this study. 
Overall, the most commonly diagnosed hepatic lesions were: suppurative to mixed hepatitis 
(88/251, 35.1%), multi-focal hepatocellular necrosis (36/251, 14.3%), and portal fibrosis with 
bile duct proliferation (32/251, 12.8%). The most common lesion in adults, yearlings, and 
juveniles was suppurative to mixed hepatitis (46/152, 30.3%; 13/24, 54.2% and 26/50, 49.1%, 
respectively). Adult horses were also frequently diagnosed with portal fibrosis and bile duct 
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proliferation (28/152, 18.4%) and hepatocellular vacuolation (20/251, 13.2%). Juveniles had 
frequent cases of multi-focal hepatocellular necrosis (10/50, 20.0%). The only lesions 
characterized in fetuses were multi-focal hepatocellular necrosis (19/25, 76.0%), suppurative to 
mixed hepatitis (3/25, 12.0%) and centrilobular hepatocellular necrosis (3/25, 12.0%)  
 
Specific histological lesions and their associated demographic characteristics are described in 
further detail in the following sections, from most to least frequent. 
 
4.4.1 Hepatitis, suppurative to mixed inflammation 
A predominantly suppurative hepatitis, with or without lymphocytes, eosinophils or 
macrophages was observed in 88/251 (35.1%) cases and was the most frequently observed lesion 
in this study. The distribution of the lesions was either primarily portal (cholangiohepatitis; 
56/88, 63.6%), multi-focal random (29/88, 33.0%), or described as focal abscesses (3/88, 3.4%). 
Fibrosis and bile duct proliferation were commonly observed in the portal distributed lesions 
(38/56, 67.9%), and ranged from being mild and localized to extensive and bridging. Bile stasis 
was also commonly seen. Mild hepatocellular lipidosis, portal edema, and hepatic necrosis were 
infrequently present. Hepatocellular necrosis with occasional foci of mineralization was 
commonly associated with multi-focal parenchymal hepatitis.  
 
Submissions occurred 1 to 10 times per year, with a peak of 10 submissions in 2013. Figure 5-2 
shows the overall increasing trend in submissions over the study years (compare to Figure 5-1 
which represents submissions for all cases over the study period). The lesion distribution was 
46/88 (52.3%) in adults, 26/88 (29.6%) in juveniles, 13/88 (14.8%) in yearlings and only 3/88 
(3.4%) in fetuses. The age range for 77 known ages was 1 month to 30 years, with a median age 
of 3 years and IQR of 7 months to 10 years. Fetal age was known in one case, at approximately 
330 days of gestation. Both submissions per year and life stage were significantly associated 
characteristics as determined by multi-variate analysis for the diagnosis of suppurative hepatitis. 
The odds ratio increased 1.07 times per year for this lesion (P = 0.005, 95% CI = 1.02 to 1.13). 
Furthermore, juveniles and yearlings both had 2.9 times increased odds of being diagnosed with 
this lesion in comparison to adults (P = 0.002 and 0.021, 95% CI = 1.45 to 5.62 and 1.17 to 7.00, 
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respectively). When the full model was tested against a more constrained model containing life 
stage only, the likelihood ratio test confirmed that the full model was better fitted (P = 0.0046). 
One large residual was observed in the full model. However, when the observation was removed, 
and the logistic model was run again, neither the odds ratios nor the P-value changed 
significantly. This observation was therefore included in the final model.  
 
Fall had the largest number of submissions (28/88, 31.8%), followed by spring and summer 
(21/88 each, 23.9%) and winter (18/88, 20.5%; Table 5-4). More than half were received as 
necropsies (45/88, 51.1%), 28/88 (31.8%) as portions and 15/88 (17.1%) were biopsy 
submissions. However, neither season nor collection method were significantly associated with a 
diagnosis for this lesion. 
 
Bacterial culture from the liver was performed in only 21 cases (23.9%; Table 5-5). Bacterial 
culture was largely unrewarding, with over half (11) reporting a negative result. Clinically 
significant isolates were found in acute cases of hepatitis, with Streptococcus equi subsp. 
zooepidemicus, Actinobacillus equuli, Listeria sp., Salmonella sp. being cultured. E. coli was 
cultured in the liver in both acute and chronic cases. 
 
Three cases of hepatic abscesses were diagnosed. One abscess was diagnosed in a seven-month-
old juvenile horse and had a positive culture for Streptococcus equi subsp. zooepidemicus. The 
remaining two cases were diagnosed in adult horses, 9 and 19 years of age. Both were female 
Quarter Horses. One of the abscesses was attributed to a foreign body peritonitis, no cause for 
the other abscess could be determined. No additional bacterial culture was performed in these 
two cases.  
 
Two cases of chronic cholangiohepatitis in an 8-year-old female Thoroughbred and a 13-year-old 
male Quarter Horse were due to cholelithiasis, with choleliths up to 10 cm in diameter found in 
the bile duct at necropsy. A 14-day-old male Thoroughbred had hepatitis associated with a 
concurrent omphalophlebitis.  
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4.4.2 Multi-focal random hepatocellular necrosis 
In 36/251 (14.3%) submissions, lesions were characterized by multi-focal random coagulative 
hepatocellular necrosis, that was occasionally accompanied by mild inflammatory infiltrates.  
 
Submissions occurred between 0 to 4 times per year, with peaks in 1996 and 1999. The diagnosis 
was most frequently made in the spring (20/55.6%) followed by summer and winter (7 cases 
each, 19.4%) and fall with 2 cases (5.6%; Table 5-4). Twenty-five cases (71.4%) originated from 
necropsies, nine cases (25.7%) from portions submissions and one case (2.9%) from biopsy. 
However, none of these characteristics were significantly associated with lesion diagnosis.  
 
This lesion occurred most frequently in fetuses (19/36, 52.8%) followed by juveniles (10/36, 
27.8%) and adults (6/36, 16.7%). Only one yearling was diagnosed with this lesion. The age 
range of 14 known individuals was between 1 month to 11 years of age, with a median age of 1 
month and an IQR of 1 month to 5 years. Nine fetuses were given estimated gestational ages, 
ranging from 180 days to 330 days, with a mean of 264.5 days (sd = 42.9). Life stage was a 
significantly associated characteristic for diagnosis with this lesion (P < 0.0001). Fetuses had 
77.1 times greater odds (P < 0.0001, 95% CI = 22.6 to 263.2) and juveniles had 6.1 times greater 
odds (P = 0.001, 95% CI = 2.1 to 17.8) when compared to adults.   
 
All nineteen submitted fetuses also had intra-nuclear eosinophilic inclusion bodies most 
consistent with EHV-1 infection. However, there was also a single case of a six-year-old male 
donkey also with similar (viral) inclusion bodies. No further testing was submitted for this case. 
Additional diagnostic testing was performed on 14 cases of suspected EHV-1 in fetuses. Eleven 
cases had tissues submitted for a fluorescent antibody test (FAT), ten of which were positive and 
three cases had liver sections submitted for immunohistochemistry (IHC) and were all positive 
for EHV-1.  
 
Five out of 36 cases (13.9%), all originating from juveniles four weeks of age and younger, 
contained intra-cytoplasmic groups of rod-shaped bacteria visualized on H&E or facilitated by 
silver stain, consistent with Clostridium piliforme infection within hepatocytes at the necrotic 
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edge. The exact etiology of hepatic lesions in the remaining five juveniles was unknown but was 
thought to have originated from a variety of etiologies: One case had a positive liver culture for 
E. coli, however, lung, spleen, and kidney all cultured Streptococcus equi subsp. zooepidemicus 
(consistent with sepsis), one other portion case was highly suspicious of sepsis, as significant 
lung lesions with intralesional bacteria were described (no culture was performed), and a third 
case was diagnosed histologically with a severe peritonitis, pleuritis, and meningitis (consistent 
with sepsis), though no bacterial culture was performed. The fourth case was described as having 
lung abscesses that cultured positive for Streptococcus equi subsp. zooepidemicus and the final 
case was of unknown etiology. 
 
4.4.3 Portal fibrosis and bile duct proliferation 
Hepatic lesions of portal fibrosis and bile duct proliferation was diagnosed in 32/251 (12.8%) 
cases and were characterized by portal fibrosis that was often extensive and bridging with bile 
duct proliferation (ductular reaction). Lesions may have also had mild hepatocellular necrosis, 
hepatocellular vacuolation, or inflammation. Megalocytosis of hepatocytes was reported in a 
single case, and bacterial culture was unrewarding when performed.  
 
The range of submissions was 0 to 4 times per year, with a peak of 4 cases in 2011. These lesions 
were most often diagnosed in the fall (11/32, 34.4%), followed by summer (9/32, 28.1%), spring 
and winter (6/32 each, 18.8%; Table 5-4), though this was not found to be statistically significant 
for lesion diagnosis. Five cases were diagnosed on biopsy submissions (15.6%), with the 
remainder as portions submissions (14/32, 43.8%) and whole-body necropsies (13/32, 40.6%).  
 
In total, 2 juveniles, 2 yearlings, and 28 adults were evaluated with this lesion. The age range 
was 1 month to 28 years, with a mean age of 11.6 years (sd = 7.1; 30 individuals with known 
ages). Seventeen males (53.1%) and 15 females (46.9%) were diagnosed. Life stage was a 
significantly associated characteristic for this lesion and adults had 5.4 times greater odds than 
juveniles (P = 0.025, 95% CI = 1.2 to 23.6). Two cases originated from the same farm and were 
both submitted only days apart in September of 1997. The remaining submissions were likely 
unrelated. 
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4.4.4 Hepatocellular vacuolation 
Submissions of hepatocellular vacuolation included all cases potentially containing lipid and 
glycogen, and where vacuolation was the dominant lesion in the liver (25 cases, 10.0 %). In 19 
cases, the vacuoles were interpreted by the pathologist based on histology to contain lipid, one 
was determined to be due to glycogen, three were interpreted as vacuolar degeneration or 
hydropic change, and two cases were not interpreted. Only four cases of presumed lipid 
vacuolation were tested with Oil Red O, and all were positive for lipid. The single case of 
suspected glycogen accumulation stained positively for Periodic Acid Schiff’s (PAS) stain and 
was cleared by PAS-diastase, consistent with intracellular glycogen. Microscopically, cases of 
hepatocellular vacuolation consisted of intra-cytoplasmic, optically clear vacuoles which ranged 
from micro-vesicles to macro-vesicles. Vacuoles were of variable sizes and ranged from being 
distinct, and round to less distinct and irregular. Nuclear placement was either central within the 
cell or eccentrically located.  Few cases also contained mild portal lymphocytic infiltrates, mild 
fibrosis, mild hepatocellular necrosis and lipofuscin pigment. Bacterial culture of the liver was 
performed in five cases and returned insignificant results.  
 
Submissions of hepatocellular vacuolation occurred 0 to 3 times per year, with peaks of 3 cases 
in 1996, 2002, and 2005. It was most frequently diagnosed in the summer months (7/25, 28.0%) 
with the remaining cases spread equally over spring, fall and winter (6/25, 24.0%; Table 5-4), 
though this distribution was not statistically significant. Approximately half of the cases (12/25, 
48.0%) were diagnosed on necropsy, 8/25 (32.0%) on portion submissions and 5/25 (20.0%%) 
on biopsies.  
 
Hepatocellular vacuolation was seen in adults (20/25, 80.0%), yearlings (2/25, 8.0%) and 
juveniles (3/26, 12.0%) but not in fetuses. The age range of equids with the lesion was 1 month 
to 31 years, with a mean age of 9.9 years (sd = 7.8). Nine animals (36.0%) were male, 15 
(60.0%) were female, and 1 was of unknown sex. Two individuals were also diagnosed with 
pituitary adenomas on necropsy.  
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Breed was a significantly associated characteristic for hepatocellular vacuolation. Donkeys 
(including Miniature Donkeys) had 29.5 times greater odds (P = 0.0001, 95% CI = 5.3 to 164.2), 
ponies had 15.7 times greater odds (P = 0.002, 95% CI = 2.7 to 90.8), Coldbloods had a 7.9 
times greater odds (P = 0.044, 95% CI = 1.06 to 58.6) and Miniature Horses had 7.4 times 
greater odds (P = 0.026, 95% CI = 1.3 to 4.0) when compared to the mixed breed/unknown 
group.  Only Percherons were diagnosed with hepatocellular vacuolation of those breeds 
included in the Coldblood group. 
 
4.4.5 Centrilobular hepatocellular necrosis 
Centrilobular hepatocellular necrosis was characterized in 24/251 (9.6%) of submissions. 
Histologically, all cases contained at least some centrilobular hepatocellular necrosis. 
Submissions may also have contained fibrosis, particularly of the terminal hepatic venule or 
sinusoidal lining, mild inflammation, and variable amounts of centrilobular (hemorrhagic) 
congestion. Of the 24 cases, 13 were due to heart failure, 10 of which had concomitant cardiac 
lesions. One case was due to neonatal isoerythrolysis. The exact etiology of liver lesions in the 
remaining 10 cases was unknown. However, three were suspected to be due to acute toxin 
exposure, and three were thought to be caused by an infectious agent resulting in disseminated 
intravascular coagulopathy (DIC), thrombosis or hypoxia due to severe pneumonia. Four cases 
were of unknown cause, and the hepatic lesions were considered unrelated to the determined 
cause of death.  
 
Submissions were observed 0 to 3 times per year, with a peak of 3 submissions in 1999 and 2006 
and were most often diagnosed in the winter (7/24, 29.2%), followed by spring, summer, and fall 
(Table 5-4). Season, however, was not a statistically significant associated characteristic of this 
lesion. Cases were all found on post-mortem exam (portions and necropsies).  
 
Lesions were seen in adults (13/24, 54.2%), juveniles (3/24, 20.8%), yearlings (5/24, 20.8%) and 
fetuses (3/24, 12.5%). The age range of 17 known individuals was from 1 month to 27 years, 
with a mean age of 7.6 years (sd = 7.4). One fetus was determined to be approximately 180 days 
in gestation. 
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4.4.6 Non-specific portal lymphocytic infiltrates 
Fifteen submissions (6.0%) with non-specific portal lymphocytic infiltrates were identified. 
Submissions were seen between 0 and 2 times per year and evenly distributed across the seasons 
(4 cases each in summer, fall, and winter, 3 cases in spring; Table 5-4). All cases were diagnosed 
on post-mortem exam (5 from portions submissions, 12 from necropsies). Microscopically, 
lesions were consistent with mild portal lymphocytic infiltrates, occasionally with eosinophils 
and in the absence of hepatic parenchymal damage and suppurative inflammation. 
 
Adult equids were diagnosed in 12 cases (80.0%), with one yearling and two juveniles. Ten cases 
were males (66.7%), four females (26.7%) and one unknown sex. The age range from 10 known 
individuals was from 4 months to 15 years, with a median age of 7 years and an IQR of 1 to 12 
years.  
 
4.4.7 Focal or multi-focal hepatitis, granulomatous 
In 15/251 (6.0%) cases, granulomatous inflammation consisting of macrophages, often with 
multi-nucleated cells and admixed with eosinophils was observed either focally or multi-focally. 
Fibrosis was frequently present (11 cases) and was associated with the inflammation, either as an 
increase in fibrotic stromal tissue or as a capsule surrounding granulomas.  
 
Submissions occurred 0 to 2 times per year, most frequently in the summer months (7/15, 
46.7%), followed by fall, winter (3/15 each, 20.0%) and spring (2/15, 13.3%; Table 5-4), though 
season was not a significantly associated characteristic. Nine cases (60.0%) were diagnosed from 
necropsies, three from portions and three from biopsies.  
 
Twelve adults (80.0%), two yearlings (13.3%) and one juvenile (6.7%) were diagnosed, seven 
males (46.7%), seven females and one of unknown sex. This lesion was not observed in fetuses. 
The age range of equids with this lesion was 3 months to 17 years, with a median age of 11 years 
and an IQR of 5 to 12 years (of 13 known individuals). 
 
39 
 
In 13 cases, the lesions were consistent with parasite migration, though only a single case had 
evidence of a parasite (Parascarus equorum) within mineralized granulomas. The exact etiology 
of the remaining two cases was not determined, but one submission was suggestive of 
Mycobacterium avium granulomas, and one was highly suspicious of a Rhodococcus equi 
infection, both based on histopathologic lesions in other organs, though liver culture was 
negative.  
 
4.4.8 Neoplasia 
Hepatic neoplasia was diagnosed in 12/251 cases (4.8%). Half of the cases (6/12) were 
diagnosed in the fall months, with three cases seen in the winter, two in the summer and one in 
the spring (Table 5-4). Three cases (25%) were diagnosed on biopsy, with the remaining 
diagnoses made on post-mortem exam. Only adults were affected, and this was significant by 
chi-square analysis (P = 0.042). The median age of affected horses was 16 years with an IQR of 
6 to 25 years (11 known ages, one unknown).  
 
Multicentric lymphoma was diagnosed in 8/12 (66.7%) cases of neoplasia. The primary process 
was always of gastrointestinal origin. Three appaloosas, three Quarter Horses, one Quarter Horse 
cross, and one American paint were affected, of which five were male, two were female, and one 
was of unknown sex. The age range for diagnosis was 4 to 27 years of age, with a mean of 13.6 
years and a median of 13 years.  
 
One case of cholangiocarcinoma was diagnosed in a 26-year-old female mixed-breed horse. 
Necropsy also revealed metastasis of the neoplasia to the lungs.  
 
Individual submissions of other (metastatic) neoplasia were diagnosed in the liver. Squamous 
cell carcinoma (SCC) was observed in a 17-year-old female Thoroughbred. Hemangiosarcoma 
was diagnosed in a 16-year-old female Quarter Horse. The primary tumor could not be 
identified, though neoplastic cells were observed in the muscle, thyroid, lung, kidney and adrenal 
gland, in addition to the liver.  A single submission of renal cell carcinoma was diagnosed in an 
adult female Quarter Horse of unknown age.  
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4.4.9 Infarction 
Three submissions of hepatic infarction were diagnosed.  Microscopically, the lesions consisted 
of a focal area of coagulative hepatic necrosis and hemorrhage, and one submission had a 
significant neutrophilic inflammatory infiltrate. Two animals were observed to have a liver lobe 
torsion at necropsy, a 4-year-old female Belgian Warmblood and the other a 24-year-old male 
Quarter Horse. The third animal was a nine-year-old male Appaloosa and was a portions 
submission with no additional information on the necropsy findings. 
 
4.4.10 Congenital microvascular dysplasia (shunt) 
A single submission of a congenital vascular anomaly was diagnosed in an eight-month-old, 
male Quarter Horse. Histologically, there was abundant, diffuse arteriolar proliferation (multiple, 
prominent and tortuous) with hepatocyte atrophy and mild portal fibrosis.  
 
4.4.11 Multi-focal eosinophilic granulomas  
A single submission of multi-systemic eosinophilic epitheliotropic disease (MEED) was 
diagnosed on post-mortem exam (necropsy). Histologically, the liver had multi-focal 
eosinophilic infiltrates, as did other organs, including the skin. The affected animal was a four-
year-old, female Quarter Horse.  
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4.4.12 Results figures 
 
 
Figure 4-1: The frequency of submissions (251 total) of equine hepatic lesions by calendar 
year submitted to Prairie Diagnostic Services Inc. (Saskatoon, SK, Canada) between 1995 
and 2014, inclusive.  
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Figure 4-2: The frequency of submissions of suppurative to mixed hepatitis (88 total) in 
equine hepatic lesions by calendar year submitted to Prairie Diagnostic Services Inc. 
(Saskatoon, Canada) between 1995 and 2014, inclusive. Multi-variate analysis (logistic 
regression) determined that the odds ratio increase 1.07 times per year for this lesion (P = 0.005, 
95% CI = 1.02 to 1.13) when life stage was combined in the model.  
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4.4.13  Results tables 
 
Table 4-1. The frequency distribution of sex by life stage for all 251 equids with 
histopathologic hepatic lesions submitted to Prairie Diagnostic Services Inc. (Saskatoon, 
Canada), between 1995 and 2014, inclusive.Life stage was determined based on the given age 
of the animal, or from information from the submitted history or necropsy report if age was not 
specified. An adult horse was any animal over the age of 24 months, a yearling was 10 to 24 
months (inclusive), and a juvenile (foal) was from birth to 9 months. 
  
Sex Life stage 
 Adult Yearling Juvenile Fetus Total 
Male 77 9 23 5 114 
Female 68 15 25 11 119 
Unknown 7 0 2 9 18 
       
Total 152 24 50 25 251 
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Table 4-2. The frequency distribution of breed by life-stage for all 251 equids with 
histopathologic hepatic lesions submitted to Prairie Diagnostic Services Inc. (Saskatoon, 
Canada), between 1995 and 2014, inclusive. Life stage was determined based on the given age 
of the animal, or from information from the submitted history or necropsy report if age was not 
specified. An adult horse was any animal over the age of 24 months, a yearling was 10 to 24 
months (inclusive), and a juvenile (foal) was from birth to 9 months. Breeds were grouped as 
follows. Hotbloods included Thoroughbreds and similar breeds (including chuckwagon ponies), 
Arabians and Morgans. Warmbloods included Quarter Horses and similar breeds (including 
appaloosa, American paints, and pintos), Belgian Warmbloods and Foreign Warmbloods. 
Coldbloods included Percherons and Clydesdales. Ponies included all animals designated as 
“pony” as well as Welsh ponies and Shetland ponies. Donkeys included all donkeys and 
Miniature Donkeys. All cross- and mixed-breeds, two Standardbreds, one Saddle Horse, one 
Icelandic Horse and one Tennessee Walking Horse, were placed in the same category with the 
unknown breeds. 
 
      
Breed Life stage 
 Adult  Yearling  Juvenile  Fetus  Total 
Hotbloods 29  2 9 2 42 
     Thoroughbreds 17  1  7  2  27 
     Arabian 9 1 2 0 12 
     Morgan 3  0 0 0 3 
Warmbloods 63 13 22 12 110 
     Quarter Horses 58  10  19 9 96  
     Belgian Warmblood 5 2 2 0 9 
     Foreign Warmblood 0 1 1 3 5 
Coldbloods 2 1  2  2 7  
Ponies 7 0 2 0 9 
Donkeys 8  1 1 0 10 
Miniature Horses 7 2 1 1 11 
Mixed/unknown  36  5 13 8 62 
      
Total 152 24 50 25 251 
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Table 4-3. The frequency distribution (and percent proportion) of histopathologic lesion 
diagnosis by life stage for all 251 equids with hepatic lesions submitted to Prairie 
Diagnostic Services Inc. (Saskatoon, Canada), between 1995 and 2014, inclusive. Life stage 
was determined based on the given age of the animal, or from information from the submitted 
history or necropsy report if age was not specified. An adult horse was any animal over the age 
of 24 months, a yearling was 10 to 24 months (inclusive), and a juvenile (foal) was from birth to 
9 months. Multi- and uni-variate analysis were performed to determine if life stage was a 
significant predictor for that lesion. The statistically significant life stages for particular lesion 
diagnoses are denoted by a ** or * if determined by multi-variate or univariate analyses, 
respectively. 
 
 Lesion Life stage 
 Adults (%) Yearling (%) Juvenile. (%) Fetus (%) Total (%) 
All lesions 152 24 50 25  251 
Suppurative to 
mixed hepatitis 
46 (30.3%) 13 (54.2%)** 26 (49.1%)** 3 (12.0%) 88 (35.1%) 
Multi-focal 
necrosis 
6 (3.9%) 1 (4.2%) 10 (20.0%)* 19 (76.0%)* 36 (14.3%) 
Portal fibrosis 
with bile duct 
proliferation 
28 (18.4%)* 2 (8.3%) 2 (4.0%) - 32 (12.8%) 
Hepatocellular 
vacuolation 
20 (13.2%) 2 (8.3%) 3 (6.0%) - 25 (10.0%) 
Centrilobular 
necrosis 
13 (8.6%) 3 (12.5%) 5 (10.0%) 3 (12.0%) 24 (9.6%) 
Non-specific 
portal hepatitis 
(lymphocytic) 
12 (7.9%) 1 (4.2%) 2 (4.0%) - 15 (6.0%) 
Granulomatous/ 
eosinophilic 
hepatitis 
12 (7.9%) 2 (8.3%) 1 (2.0%) - 15 (6.0%) 
Neoplasia 12 (7.9%)* - - - 12 (4.8%) 
Infarction (focal 
necrosis) 
3 (2.0%) - - - 3 (1.2%) 
Microvascular 
dysplasia 
(congenital) 
- - 1 (2.0%) - 1 (0.4%) 
Multi-focal 
eosinophilic 
granulomas 
1 (0.7%) - - - 1 (0.4%) 
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Table 4-4. The frequency distribution of breed by life-stage for all 251 equids with 
histopathologic hepatic lesions submitted to Prairie Diagnostic Services Inc. (Saskatoon, 
Canada), between 1995 and 2014, inclusive. From the date of the pathology report, year, and 
season of submission were determined. "Spring" was defined as the months of March, April, and 
May, "summer" as the months of June, July and August, "fall" was defined as September, 
October, and November, and "winter" was defined as December, January, and February. 
 
Lesion  Season 
 Spring Summer Fall Winter 
Suppurative to mixed hepatitis 21 21 28 18 
Multi-focal necrosis 20 7 2 7 
Portal fibrosis with bile duct proliferation 6 9 11 6 
Hepatocellular vacuolation 6 7 6 6 
Centrilobular necrosis 6 6 5 7 
Non-specific portal lymphocytic infiltrates 3 4 4 4 
Granulomatous/eosinophilic hepatitis 2 7 3 3 
Neoplasia 1 2 6 3 
Infarction (focal necrosis) 0 1 2 0 
Microvascular dysplasia 0 0 1 0 
Multi-focal eosinophilic granulomas 0 0 1 0 
  
    
Total 65 64 68 54 
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Table 4-5. Bacterial culture results of equine liver from submissions of suppurative to 
mixed hepatitis submitted to Prairie Diagnostic Services Inc. (Saskatoon, Canada), between 
1995 and 2014, inclusive. Significant bacterial isolates are those known to cause hepatic lesions 
in equids. 
 
 Submissions 
cultured 
Submissions with 
negative culture 
Submissions with 
significant 
isolates 
Significant 
isolates identified 
Acute 
cholangio-
hepatitis 
3 0 3 S. equi subsp. 
zooepidemicus  
A. equuli, E. coli 
Chronic 
cholangio-
hepatitis 
8 5 1 E. coli (few) 
Acute 
multi-focal 
hepatitis 
10 6 4 Listeria sp., 
Salmonella sp., 
S. equi subsp. 
zooepidemicus, A. 
equuli, E. coli. 
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4.5 Discussion 
 
We performed a 20-year retrospective study of histopathologic liver lesions in equids, including 
fetuses, based on cases submitted to PDS Inc, a diagnostic lab serving the public in western 
Canada. Lesions of suppurative (to mixed) hepatitis, multi-focal necrosis, portal fibrosis and bile 
duct proliferation and hepatocellular vacuolation were the most common lesions described and 
constituted almost 75% of all submissions. Lesions of centrilobular necrosis, non-specific portal 
lymphocytic infiltrates, granulomatous hepatitis, neoplasia, and infarction were less common. 
Single submissions of microvascular dysplasia and multi-systemic epitheliotropic eosinophilic 
disease were diagnosed. Statistics were performed to identify possible characteristics associated 
with the diagnosis of these lesions. Life stage was consistently associated with several lesion 
diagnoses whereas sex, season and collection method were not. Breed was significantly 
associated with only one lesion diagnosis, hepatocellular vacuolation.   
 
Age and season are known to be associated with specific lesions or etiologies within the equine 
liver. For example, Tyzzer’s disease and EHV-1 are known to affect neonatal foals, and EHV-1 
is known to be an important cause of equine abortion.108,178,270,273 Both etiologies often coincide 
with foaling season. In this study, age and lesion association in the equine liver were consistent 
with what has been reported in the literature. In general, lesions suggestive of infectious agents 
were more commonly reported in younger animals, and fibrosis was more commonly reported in 
older animals. 
 
Suppurative to mixed hepatitis and multi-focal necrosis were caused by a variety of etiologies in 
this study and together made up nearly half of all submissions. They were also the most frequent 
lesions observed in fetuses and juveniles. Suppurative to mixed hepatitis commonly occurs 
secondary to a variety of bacterial infections. It is interesting to note that the number of 
submissions receiving this diagnosis steadily increased over the study period. This is most likely 
due to an actual increase in the incidence of this lesion, as the overall number of submissions of 
hepatic lesions per year has remained steady over the study period (except a small peak in 2005). 
Thus, pathologists and practitioners are encouraged to continue culturing liver (biopsy) 
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submissions whenever possible and to monitor for any changes in bacterial species and antibiotic 
resistance. Unfortunately, over 76% of the submitted specimens in this category were not 
cultured and over half of those cultured yielded negative or insignificant results. In many 
instances, only formalin-fixed biopsy or portion submissions were received. Therefore, the 
majority of cases in this category were without a specific bacterial cause although bacterial 
sepsis and ascending bacterial infections were often speculated in the pathology reports. It is 
often difficult to obtain positive culture results from liver samples submitted by veterinarians as 
they are commonly performed after administered antibiotics fail to achieve significant 
improvement. Pathologists are, therefore, reminded to submit liver samples from necropsies for 
bacterial culture more often.  Bacterial culture of liver samples is not only important in 
determining the etiology of hepatic lesions but could also guide practitioners in selecting an 
appropriate antibiotic(s). 
 
Significant bacterial isolates cultured from the liver in this study included E. coli, Salmonella sp., 
Listeria sp., Actinobacillus equuli and Streptococcus equi subsp. zooepidemicus. These isolates 
are consistent with what has been reported previously in horses and are considered enteric or 
septicemic in origin.4,52,68,144,182,222 A few of the submissions of hepatitis in the current study also 
had concurrent gastrointestinal findings on post-mortem examination, ranging from enteritis, 
impaction, and obstruction caused by a high parasite burden. It has been shown that horses with 
gastrointestinal disease had significantly elevated serum hepatic enzyme activity, suggestive of 
hepatic injury.67 Suppurative cholangiohepatitis has been associated with proximal enteritis in 
horses of one study.68 Secondary hepatic lesions due to a primary gastrointestinal process may be 
a result of hypoxia, ischemia, endotoxemia, biliary obstruction or ascending bacterial 
infection.290 The most common cause of death in horses, second only to old age, is colic and 
gastrointestinal disease.282 Mortality due to colic in a normal farm population was 0.7 deaths per 
100 horse years, with a fatality rate of 6.7%.282 Human patients with gastrointestinal disease such 
as inflammatory bowel disease and celiac disease frequently have concurrent hepatobiliary 
lesions.316 Therefore, primary gastrointestinal disorders are likely major contributors to hepatic 
lesions, and ultimately hepatic disease in horses. 
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Septicemia is an important cause of illness and death in young animals, with mortality reported 
in up to 75% in cases.164  A study out of Ireland found that foals in their first year of life had 
morbidity associated with an infectious etiology in 46.5% of cases.103 Young animals are 
especially at risk, as their immune systems are still naive. Inadequate or late colostrum intake 
may decrease the number of immunoglobulins transferred between mare and neonate.223 
Furthermore, the antibody profile of neonates is different from adult horses,249 making them 
more at risk for infectious agents to which adult horses are usually resistant.  Bacterial sepsis 
may cause secondary lesions in the liver through changes in liver hemodynamics, by direct 
injury of the hepatocytes, or both.312 Not only are bacteria themselves directly damaging to cells, 
but bacterial products and inflammatory mediators have also been shown to cause hepatic 
damage and inflammation.316 In human autopsy studies of patients that died of sepsis, hepatic 
lesions included portal inflammation, cholangiohepatitis, hepatocellular apoptosis, lobular 
inflammation, and steatosis.163 In this study, it is likely that many horses had septicemia, but this 
cannot be conclusively confirmed.   
 
The most commonly identified causes of random multi-focal necrosis were EHV-1 infection, 
followed by Clostridium piliforme, and both etiologies produced characteristic histological 
lesions and had typical age correlations. Equid herpes virus-1 is an important cause of pregnancy 
loss in mares and was the leading cause of hepatic lesions in aborted fetuses in this study.178,273 
Typical lesions of EHV-1 infection in the liver include random foci of hepatocellular necrosis 
with eosinophilic intranuclear inclusion bodies.56,61 Since the virus often results in abortion 
acutely during infection, suppurative inflammation is not a consistent feature of the lesion, 
though some neutrophils may be present.  Of the cases affected by EHV-1, all fetuses (19 in 
total) had characteristic and easily identifiable intra-nuclear inclusion bodies while no inclusions 
were found in juveniles (total of five submissions). It is not uncommon for inclusion bodies to be 
absent with viral infections as they are often found only during the early stages of the disease.61 
It is likely that these neonatal foals had a longer duration of infection since they were likely 
infected in utero and survived for few days after birth. Although not statistically significant in 
the current study, EHV-1 was most often diagnosed in March and April, with fetuses being 
aborted between 210 to 330 days of gestation. This seasonality is similar to what others have 
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described in the literature.178,258,273 This seasonality may reflect the more natural time for 
pregnancy and parturition in mares without manipulation of mare fertility, as often practiced to 
produce an early-season foal. Although no breed predisposition could be statistically identified, 
Tengelsen et al.,273  reported that Standardbreds were twice as likely as other breeds to be 
affected by EHV-1. Differences in breed susceptibility may reflect regional differences in 
desired breeds and management practices.  
 
Portal fibrosis and bile duct proliferation was a relatively common diagnosis representing 12.7% 
of all submissions. In almost half of the cases, the exact etiology could not be identified, and the 
remainder were suspected to be due to chronic exposure to hepatotoxins, such as pyrrolizidine 
alkaloid-containing plants, alsike clover, and aflatoxins. Because of the delay (weeks to months) 
in the onset of clinical signs after exposure to a hepatotoxin, the original cause of the toxicosis is 
often difficult to identify. 107 Therefore, diagnosis is predominantly made based on history and 
supporting histopathology. Furthermore, as histopathologic lesions are due to long-term 
exposure, it is not surprising that these lesions were found in more mature animals. Typical 
histopathologic lesions of portal fibrosis and biliary hyperplasia are consistent with pyrrolizidine 
alkaloid toxicosis, alsike clover toxicosis, and chronic aflatoxicosis.3,63,203 Also, the 
histopathologic lesions of pyrrolizidine alkaloid toxicosis and aflatoxicosis may include the 
presence of megalocytosis.3 All the cases in the current study contained evidence of portal 
fibrosis and biliary hyperplasia, in the absence of any significant inflammation. Only a single 
case described megalocytosis, suggesting that perhaps alsike clover toxicities, versus 
pyrrolizidine or aflatoxin, are more common in this region than initially thought. Indeed, Nation 
described a regional distribution of alsike clover-like hepatic pathology in Northwest Alberta, a 
region that is included in this study. 203  
 
In those submissions in which hepatocellular vacuolation was the dominant lesion, the majority 
were interpreted to be lipid by the examining pathologist, though only four submissions were 
confirmed with Oil Red O stain. Similar to other studies of hepatic lipidosis in equids, 
104,139,199,200 Donkeys (and Miniature Donkeys), ponies (including Shetland and Welsh Ponies) 
and Miniature Horses had significantly increased odds of being diagnosed with this lesion. In 
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fact, of the seven donkeys and three Miniature Donkeys in this study, the only diagnosed lesion 
was that of hepatocellular vacuolation. Despite having only two Percherons (Coldblood group) 
with this lesion in the current study, statistical analysis showed that this breed is more likely to 
be affected by hepatic vacuolation. However, it is more probable that the vacuolation is of 
secondary nature and represents hepatic lipidosis as both horses likely had a negative energy 
balance. One of these Percherons was a submitted pregnant mare, and had lesions consistent with 
acute enteritis and sepsis, with Salmonella sp. isolated from the gastrointestinal tract and uterus. 
The second individual was a yearling, with extensive and severe bronchointerstitial pneumonia, 
suspicious for influenza A virus, though it was not positive when tested with IHC.  
 
Hepatic lipidosis in equids is due to a negative plane of nutrition, which may be due to anorexia, 
pregnancy or lactation, or, more often, secondarily to a systemic disease such as parasitism, 
gastric impaction, septicemia, colitis, esophageal obstruction and pituitary adenoma.200 In a study 
of 23 Miniature Horses, enterocolitis was the most common primary disease causing lipidosis.199 
In the current study, only one mare with hepatic vacuolation was reported to be pregnant, and 
one mare was potentially still nursing. Two submissions had concurrent pituitary adenomas and 
concomitant hirsutism. No additional attempts were made in this study to further characterize the 
nature of hepatocellular vacuolation, as few had confirmed lipid or glycogen vacuoles and 
reports of antemortem clinical signs and diagnostics could not be confirmed. 
  
Centrilobular necrosis can be seen with conditions causing low oxygen tension such as heart 
failure, DIC, and severe acute anemia.61 Centrilobular hepatocytes are also prone to necrosis 
because they contain the highest concentration of cytochrome p450 enzymes compared to other 
zones within the liver.207 In this study, this lesion primarily occurred in association with heart 
failure although it was also diagnosed with neonatal isoerythrolysis. Pathology reports also 
speculated about toxin exposure, DIC, and severe pneumonia as potential causes.   
 
Non-specific portal lymphocytic hepatitis (also known as reactive hepatitis) is characterized by 
the presence of few lymphocytes in portal areas. This can be considered a normal finding or 
could be related to the response of the liver to systemic illness.166 Only 15 submissions were 
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identified in this study, which is likely an under-representation of the actual number of cases as 
not all pathologists report this as a significant lesion.   
 
Granulomatous inflammation was an uncommon type of inflammatory lesion in this study. 
Granulomas are aggregates of histiocytes and occur as a result of chronic antigenic stimulation, 
often due to mycobacteria, fungi or parasites.53 Granulomatous inflammation made up only 6.0% 
of the hepatic lesions observed, but occurs in between 2.4% and 15% of biopsy specimens in 
humans.53 In equids, these lesions are thought to arise from parasite migration which is often 
considered an incidental finding at necropsy.33,263 Parasites capable of causing these lesions in 
equids includes Strongylus vulgaris, Strongylus equinus, Strongylus edentatus, Parascaris 
equorum and Habronema sp..183,263,286 In this study, 13 cases were thought to be due to parasite 
migration, yet only one horse had cross sections of Parascaris equorum within the 
granulomatous nodules. In another study, only one of 11 horses had evidence of parasites within 
granulomatous lesions (schistosome egg remnants).33 In general, however, most cases of 
parasitic hepatic lesions do not cause clinical disease, though in rare instances animals may 
succumb to liver failure, circulatory disturbances or poor body condition as a result.33 
 
Primary hepatic neoplasia is rare in horses,17 and cholangiocarcinoma was diagnosed only once 
in 12 cases of hepatic neoplasia in this study. The most diagnosed neoplasm in the equine liver in 
the current study was multicentric lymphoma, a relatively common neoplasm in horses. Only one 
case of metastatic SCC was diagnosed in this study and was of gastric origin. However, SCC was 
the most common malignant neoplasm in one study involving 241 equids, though the most 
common primary site was the bladder.192 One case of hemangiosarcoma involving the liver was 
found in this study. The prevalence of hemangiosarcoma in horses ranges between 0%- 0.7% and 
the liver has been described as a site of metastasis.96 Also, one case of renal cell carcinoma was 
found in the liver in the current study, and the lung and liver are known to be the most common 
sites of metastasis of renal cell carcinoma in equids.157 In conclusion, though neoplasia is a 
relatively rare occurrence in horses, the prevalence and behavior in this study are in alignment 
with what is currently known. 
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Three cases of infarction and a single case each of congenital microvascular dysplasia and 
MEED were observed in the current study. Hepatic infarction is uncommon, and the low 
incidence in comparison to other organs has been ascribed to the unique characteristics of hepatic 
vascularization.42 Two of the affected animals in the current study had infarctions due to a liver 
lobe torsion. Congenital microvascular dysplasia is a rare condition of young foals and 
infrequently reported in the literature.209 One case of MEED, also in a Quarter Horse, has been 
described from the local equine population in Saskatchewan.41 The particular animal was treated 
and survived and was, therefore, not included in this study. However, most equids do not survive 
the disease, despite treatment.41 
 
In general, there is a good correlation between hepatic biopsy and necropsy findings.275,303 In this 
study, biopsy submissions comprised only a small proportion of all collected specimens but were 
often able to detect the major lesions. Biopsy submissions of suppurative or granulomatous 
inflammation, fibrosis and bile duct proliferation, hepatocellular vacuolation, necrosis and 
diffuse neoplasia (lymphoma) were detected in this study.  This is similar to what West 
described, where they reported that necrosis and fibrosis were reliably detected in biopsy 
submissions, though the cause of the lesion could not always be ascertained.303  
 
Within the current study, some limitations were identified. These include the retrospective nature 
of the study, and the diverse nature of many lesions in this study, making them sometimes 
difficult to place into a respective lesion category. Some limitations of the statistical analysis 
were also identified. Statistical analysis often involved comparison of small groups, which may 
have limited the statistical power. This was the case for certain breed groups, despite combining 
like breeds together. Furthermore, the regional nature of this study may not exactly represent 
disease prevalence for the North American horse population as only submissions to the 
diagnostic service in Saskatoon were reviewed. Also, these submissions may not reflect the 
distribution of cases in a true population as submissions are dependant on factors such as the 
attitudes of owners and submitting practitioners, the distance to travel for a necropsy and the 
frequency of voluntarily donated cases. Lesion distribution in a true population is unknown. 
Therefore, all the other lesions collectively became the reference group for statistical analysis, 
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and this reference group likely does not reflect lesion prevalence in a true population. In 
addition, the statistics performed were done in comparison only to what was present within this 
submitted population. For example, statistical analysis of breed susceptibility to a lesion 
diagnosis was done in relation to the “unknown” breed group. Even though the “unknown” breed 
group likely contains the largest variety of breeds (mixed-, cross- and unknown-breeds), the 
distribution of breeds in the “unknown” group is not the same as one would expect in a true 
population.  
 
Potential future work could involve a more prospective approach, by correlating the variety and 
severity of clinical signs with antemortem, serial blood evaluation (serum biochemistry and 
complete blood count) and biopsy results with survival times and post-mortem findings. 
Furthermore, it would be interesting to correlate lesions observed by ultrasonography, biopsy and 
post-mortem examination in an attempt to provide a more sensitive antemortem tool to 
diagnosing hepatic disease in horses.  
 
This is the first retrospective study of hepatic lesions in equids from western Canada. Life stage 
was statistically associated with several lesion types, including suppurative to mixed hepatitis 
(juveniles, yearlings), portal fibrosis and bile duct proliferation (adults), centrilobular necrosis 
(juveniles, fetuses), and neoplasia (adults). Several breeds were significantly associated with 
hepatocellular vacuolation. Therefore, the findings in this study, though specific to a regional 
population in western Canada, are in alignment with what we currently know about disease in 
equids, suggesting that the regional population in this study shares similarities with the equine 
population in general, with regard to hepatic disease.  
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4.7 Supplemental Materials 
 
Supplemental Table 4-1. The P-values for the test of significance for individual 
characteristics per lesion type by univariate analysis. Chi-square analysis was carried out for 
each lesion to determine if the tested characteristic (breed, life stage, sex, year of lesion diagnosis 
and season) was significantly associated with the occurrence of that lesion in comparison to all 
other lesion groups. Potential significant characteristics were identified at a relaxed level of 
significance (P ≤ 0.2) and further evaluated by multi-variate analysis. The final model building 
included a more restrictive level of significance (P ≤ 0.05). The P – value is the probability of 
there being no difference in the distribution of that diagnosed lesion by the tested characteristic. 
 
Breeds were grouped together as follows. Hotbloods included Thoroughbreds and similar breeds 
(including chuckwagon ponies), Arabians and Morgans. Warmbloods included Quarter Horses 
and similar breeds (including appaloosa, American paints, and pintos), Belgian Warmbloods and 
Foreign Warmbloods. Coldbloods included Percherons and Clydesdales. Ponies included all 
animals designated as “pony” as well as Welsh ponies and Shetland ponies. Donkeys included all 
donkeys and Miniature Donkeys. All cross- and mixed-breeds, two Standardbreds, one Saddle 
Horse, one Icelandic Horse and one Tennessee Walking Horse, were placed in the same category 
with the unknown breeds. Life stage was determined based on the given age of the animal, or 
from information from the submitted history or necropsy report if age was not specified. An 
adult horse was any animal over the age of 24 months, a yearling was 10 to 24 months 
(inclusive), and a juvenile (foal) was from birth to 9 months. 
 
Microvascular dysplasia and multi-focal eosinophilic granuloma lesions could not be tested as 
they were only represented by a single submission each.  
 
(table on following page) 
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Lesion Characteristic tested for significance 
 breed 
(grouped) 
life stage sex year season collection 
method 
 
Hepatitis 
(suppurative to 
mixed) (n = 88) 
0.213 0.001 0.420 0.140 0.672 0.273 
Multi-focal 
necrosis  
(n = 36) 
0.392 0.000 0.001 0.877 0.000 0.058 
Biliary fibrosis 
with bile duct 
proliferation  
(n = 32) 
0.090 0.008 0.211 0.908 0.643 0.156 
Hepatocellular 
vacuolation  
(n = 26) 
0.000 0.113 0.299 0.566 0.894 0.562 
Centrilobular 
necrosis (23) 
0.345 0.826 0.906 0.868 0.718 0.157 
Non-specific 
portal hepatitis 
(lymphocytic) (n 
= 15) 
0.157 0.381 0.219 0.580 0.936 0.305 
Granulomatous/ 
eosinophilic 
hepatitis  
(n = 15) 
0.737 0.238 0.994 0.378 0.252 0.514 
Neoplasia  
(n= 12) 
0.480 0.042 0.919 0.627 0.221 0.311 
Infarction (focal 
necrosis) (n = 2) 
0.859 0.726 0.298 0.393 0.610 0.778 
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CHAPTER 5:  INTRODUCTION TO CHAPTER 6 
 
The previous study (chapter 4) investigated the types of lesions in equids from western Canada. 
In general, the diagnosis and treatment of hepatic disease in equids is often delayed as clinical 
signs are vague and occur after a significant loss of hepatic function. Treatment is mainly only 
supportive.  
 
Metallothionein (MT) has been investigated in extensively in human hepatic disease, especially 
as a possible treatment for chronic fibrotic diseases. The following chapter investigates the 
potential role of MT in chronic hepatic lesions in equids. Ultimately, can MT be utilized as a 
possible treatment for chronic equine liver disease, independent of the etiology? As the results of 
the previous study were in alignment with what we understand about liver disease in equids from 
the literature, the results of the MT study may also apply to the equine population in general.  
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6.1 Abstract 
 
Chronic liver disease is an important cause of illness in horses and may result in mortality in up 
to 25% of affected animals. Metallothionein (MT) is a highly conserved intracellular protein with 
a high binding affinity for divalent cations that has been shown to play a major role in 
inflammation and cellular regeneration. This study aimed to evaluate the role of MT in horses 
affected by chronic hepatic lesions by evaluating the relationship between hepatocyte MT 
expression, assessed by immunohistochemistry (IHC), and the degree of inflammation, fibrosis 
and bile duct proliferation in 77 selected cases. In addition, the proliferation of hepatocytes, bile 
duct epithelium, and inflammatory cells was determined using IHC for Ki-67, a protein 
expressed during all active stages of the cell cycle. Inflammation and fibrosis were given scores 
from 0 to 3 depending on severity and bile duct proliferation was assessed as the presence or 
absence of proliferation, with four bile ducts per field being the cut-off value. Increased MT 
expression was observed in 73 of 77 (94.8%) cases. Ki-67 expression was seen in resident 
Kupffer cells (42/77 cases, 54.6%), bile duct epithelium (10/77 cases, 13.0%), and hepatocytes 
(8/77 cases, 10.4%). Median MT expression was higher in cases containing lymphocytic 
infiltrates compared to cases with no lymphocytic infiltrate (P < 0.05) and all foci showed Ki-67 
staining lymphocytes (39/77 cases, 50.7%), Metallothionein expression was also significantly 
associated with Ki-67 staining in bile duct epithelium and Kupffer cells. These results suggest a 
putative role for MT during liver inflammation and proliferation of bile duct epithelia in horses. 
 
 
Key Words: bile duct, equine, fibrosis, immunohistochemistry, Kupffer cells, liver, lymphocytes, 
metallothionein. 
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6.2 Introduction  
 
Liver disease is an important cause of illness in horses. It affects all ages, breeds, and sexes and 
may result in fatality in 25% of cases.87 Causes of chronic hepatic disease in horses include 
aflatoxicosis,63 pyrrolizidine alkaloid toxicity,274 and cholelithiasis,144 among others. Because of 
the lack of specificity in clinical signs, liver disease diagnosis is largely based on biopsy and 
serum biochemical analyses.19 In general, most signs of hepatic failure appear suddenly, 
regardless of the cause and duration of the underlying disease, after the loss of more than 75% of 
the functional capacity of the liver.19 Irrespective of the cause, the prognosis of hepatic disease 
depends on the severity of histological lesions. Moderate or severe hepatic fibrosis has been 
associated with significantly higher mortality rates.87 Furthermore, the exact etiology of chronic 
liver disease in horses is rarely identified, which limits treatment options. 
 
Metallothionein (MT) was first identified in 1957 as a cadmium- and zinc-binding protein 
produced in the equine renal cortex.147 It is a low molecular weight, highly conserved 
intracellular protein with high binding affinity for divalent cations, especially copper, cadmium, 
and zinc.277 Virtually all eukaryotic organisms, as well as some prokaryotic organisms,  express 
MT.214 Four major isoforms of MT exist in mammals (MT-1, -2, -3 and -4), of which MT-1 and -
2 are most abundant in mammalian cells and are considered a single MT due to their high 
homology.215,278 Most mammalian cells express low levels of MT, but there is tissue specificity 
to expression. Liver MT is predominantly associated with copper and zinc, whereas kidney MT 
binds mainly copper, cadmium, and zinc.48  
 
Metallothionein is typically found in the cytosol of resting, non-proliferating cells, but can be 
translocated to the nucleus during cell proliferation and differentiation.3 Intranuclear localization 
of MT is thought to be associated with gene expression during the cell cycle, as a mechanism to 
protect DNA from damage and cell apoptosis.47 Elevated levels of intra-nuclear MT may be 
related to an increased demand for zinc during rapid growth as zinc is required for transcription 
factors and enzyme function.47 Furthermore, the presence of MT within the nucleus of human 
neoplastic cells is indicative of their mitotic activity, as MT immunostaining was most intense at 
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the proliferative edge of malignant tumors.46 In addition, a four-fold increase in cellular MT 
levels was measured in proliferating liver cells when compared to MT levels in resting cells.264 
MT’s role in carcinogenesis has also been suggested, and in vitro studies have postulated that 
p53 and the estrogen-receptor may be involved in the induction of MT in human neoplastic 
epithelial cells.48  
 
Metallothionein gene expression can be induced by various hepatotoxic molecules such as heavy 
metals, carbon tetrachloride, and ethanol, as well as certain cell stressors including cellular 
starvation and hydric stress.277 Studies have shown that it may play a major role as an anti-
inflammatory agent.132,133 For example, MT appears to be protective against lipopolysaccharide 
(LPS)-induced acute lung inflammation when compared to MT-knock out mice.271 Several pro-
inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-α (TNFα) and 
interferon-γ (IFNγ) have been shown to induce the expression of MT.70 The MT gene contains 
several response elements that upregulate its transcription, including glucocorticoid response 
elements, metal response elements, and an anti-oxidant response element.69 
 
Despite strong evidence of the involvement of MT in inflammation, cell regeneration and 
neoplasia, 50 years of research has not yet delivered any definitive knowledge on MT's 
function,214 though its highly conserved structure and widespread prevalence suggests it has an 
important evolutionary role. It has been the topic of several review papers.57,214,278  
 
Recent work by Sridharan et. al.262 has shown an interesting, positive correlation between MT 
expression and hepatocyte regeneration and inflammation in chronic liver disease in dogs. With 
the growing evidence that MT plays a role in hepatic inflammation and fibrosis, the present study 
aimed to explore its role as a defense mechanism in chronic hepatic disease of horses. This was 
accomplished by evaluating the relationship between hepatocyte MT expression by 
immunohistochemistry and the degree of hepatic inflammation, fibrosis, bile duct proliferation, 
and hepatocellular proliferation in cases of equine liver disease.  
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6.3 Material and Methods 
 
6.3.1 Case selection and histological scoring 
Pathology reports from the archives at Prairie Diagnostic Services, Inc. (PDS). (Saskatoon, SK, 
Canada) between January 1, 1995, and December 31, 2014, were reviewed for cases of chronic 
equine liver disease by the presence of fibrosis (JNCV). These cases were then reviewed by 
hematoxylin and eosin (H&E) slide evaluation and were included in the study if they contained 
at least minimal fibrosis, with or without inflammation or bile duct proliferation (JNCV and 
ANA). Tissues were included in the study if a minimum of 1 cm2 was available for assessment 
and no autolysis was seen histologically.  
 
In each section, hepatic inflammation, fibrosis, and bile duct proliferation were scored by two 
independent pathologists (ALA and ANA)  using a grading scheme modified after Sridharan et 
al. (Figs. 4-1 to 4-9).262 Hepatic inflammation was subjectively scored as 0, 1, 2, or 3 based on 
the assessment of the entire H&E section. A score of 0 indicated the absence of inflammation, a 
score of 1 indicated the presence of inflammation in < 10% of the section, a score of 2 indicated 
the presence of inflammation in 11% to 50% of the section and a score of 3 indicated > 50% of 
the section was affected. Similarly, fibrosis was scored 0, 1, 2 or 3 based on the assessment of 
the same sections stained with Masson’s Trichrome stain. A score of 0 indicated the absence of 
fibrosis, a score of 1 indicated the presence of periportal fibrosis, a score of 2 indicated the 
presence of fibrosis extending away from portal tracts into the parenchyma, and a score of 3 
indicated the presence of bridging fibrosis. Bile duct proliferation was evaluated by counting the 
number of bile duct profiles in 5 arbitrary fields that contained at least one bile duct, at 400x 
magnification. The number of bile ducts counted per pathologist was then averaged, and the 
cases were subsequently divided into two groups based on the presence or absence of bile duct 
proliferation to improve statistical power. Cases with greater than 4 bile ducts per field were 
considered to have bile duct proliferation, whereas cases with 0 to 4 bile ducts per field were 
regarded as not proliferated. The cut-off value of four bile ducts per field was determined by 
utilizing the bile duct counts of six histologically normal liver sections (ten random fields per 
section) measured by both pathologists. Four or fewer bile ducts per field were found in 95% of 
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the 60 counted fields.  
 
6.3.2 Immunohistochemistry for metallothionein and Ki-67 
Immunohistochemistry for MT and Ki-67 was performed at the PDS laboratory using the 
following protocol, as previously described (with modifications).118,231 Consecutive 5 μm 
sections from formalin-fixed, paraffin embedded tissue blocks were cut and mounted onto 
charged slides (ProbeOn Plus or SuperFrost Plus, Fisher) and oven baked at 60° C for 60 
minutes. Tissue sections were subsequently deparaffinized in xylene for 5 minutes, followed by 
rehydration in successive graded ethanol (5 minutes each: 100%, 95%, 70% ethanol) and then 
rinsed in distilled water. The tissue sections were then placed in 3% hydrogen peroxide solution 
(in methanol) for 10 minutes, to block any non-specific endogenous peroxidase activity and then 
rinsed twice in phosphate buffered saline with Tween 20 (PBST) for 5 minutes. Heat-induced 
antigen retrieval was performed in a water bath (Dako PT Link) at 97° C in 
Tris/ethylenediaminetetraacetic acid (EDTA) buffer (pH 9) for 20 minutes and allowed to cool in 
IHC buffer.   
 
The MT primary antibody (clone E9, mouse anti-horse MT-1 and MT-2, monoclonal IgG1, 
Dako) was diluted 1:1000 in antibody diluent (Dako) and incubated on the slides for 30 minutes 
at room temperature. Incubation for the Ki-67 primary antibody (clone MIB-1, mouse anti-
human, monoclonal IgG1, Dako) was performed overnight at 4° C and with a 1:50 dilution in 
antibody diluent. After incubation with primary antibody had been completed, slides were rinsed 
3 times for 5 minutes with PBST and incubated with Dako Envision+ System. Color 
development was performed using diaminobenzidine (DAB) substrate buffer and DAB 
chromagen as per manufacturer’s instructions. Slides were counter-stained with hematoxylin at 
room temperature for 4 minutes, rinsed with water and mounted with coverslips.  
 
Six histologically normal liver samples from horses obtained during necropsy were stained for 
MT and Ki-67 expression. Positive control samples for MT staining included equine skin and 
kidney as previously described.160,252 Positive control samples for Ki-67 staining included equine 
duodenum with Peyer’s patches. Appropriate negative sample controls were performed by 
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omission of the primary antibody, as well as by substitution of the primary antibody by an 
irrelevant monoclonal IgG antibody. (MT protocol development was performed by JNCV). 
 
6.3.3 Scoring of hepatic metallothionein and Ki-67 expression 
Metallothionein expression in hepatocytes was evaluated by counting the number of positive 
cells utilizing an intra-ocular grid at 400x measuring 25 µm2 (JNCV). Ten fields were counted in 
each section in a diagonal square zig-zag pattern, and a mean number per field was calculated. A 
mean of 104.5 hepatocytes was counted within the 25 µm2 grid. Ki-67 expression was evaluated 
by noting the presence or absence of nuclear staining within hepatocytes, Kupffer cells, biliary 
epithelium and any lymphocytic infiltrates within the entire liver section(s) (JNCV). 
 
6.3.4 Rhodanine staining for copper 
Ten slides with elevated MT expression were stained with rhodanine stain as previously 
described.248 Copper content was assessed subjectively by evaluating the slides with light 
microscopy (JNCV). 
 
6.3.5 Statistical analysis 
Statistical analysis was performed using Stata 14.2 (StataCorp, College Station, Texas, USA) 
(JCSH and JNCV). Inter-rater agreement between the pathologists was determined by calculating 
a kappa score for each of inflammation, fibrosis and bile duct proliferation. The kappa score was 
interpreted according to Landis and Koch.167 A Spearman’s Rank test was used to determine the 
presence of correlation between inflammation, fibrosis, and bile duct proliferation. The data on 
MT expression was not normally distributed. Therefore, non-parametric statistics were used. A 
Dunn’s test with a post-hoc Sidak adjustment (to account for multiple comparisons) was used for 
comparing group differences in hepatocyte MT expression by inflammation score (0 to 3) and 
fibrosis score (0 to 3) determined by each pathologist separately. A Mann-Whitney U-test was 
used to assess potential differences in hepatocyte MT expression by nuclear Ki-67 expression 
(presence/absence) within hepatocytes, bile duct epithelium, intra-sinusoidal Kupffer cells and 
lymphocytic infiltrates. Additionally, a Mann-Whitney U-test was used to assess potential 
differences in hepatocyte MT expression by the presence or absence of bile duct proliferation 
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determined by each pathologist separately. The six histologically normal liver samples were not 
included in the statistical analysis. In all analyses, the results were considered statistically 
significant when P < 0.05. 
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6.3.6 Methods Figures 
 
 
 
Figure 6-1: Equine liver. A representative image of a histologically normal liver section 
(hematoxylin & eosin, 100x). There is no evidence of inflammation present (inflammation score 
0), and no bile duct proliferation is observed. 
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Figure 6-2: Diseased equine liver. Scoring system for equine hepatic disease, inflammation 
score 1.  There is mild inflammation occupying < 10% of the section. (hematoxylin & eosin, 
100x). 
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Figure 6-3: Diseased equine liver. Scoring system for equine hepatic disease, inflammation 
score 2. Approximately 11% to 50% of the section is affected by inflammation (hematoxylin & 
eosin, 100x). 
 
71 
 
 
 
Figure 6-4: Diseased equine liver. Scoring system for equine hepatic disease, inflammation 
score 3. Greater than 50% of the section is affected by inflammation. (hematoxylin & eosin, 
100x). 
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Figure 6-5: Diseased equine liver. Scoring system for equine hepatic disease, bile duct 
proliferation.  Multiple bile duct profiles are evident in this photomicrograph. (hematoxylin & 
eosin, 100x). 
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Figure 6-6: Normal equine liver. Scoring system for equine hepatic disease, fibrosis score 0.  
(Masson’s trichrome stain, 100x).  
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Figure 6-7: Diseased equine liver. Scoring system for equine hepatic disease, fibrosis score 
1.  Mild increase in portal collagen. (Masson’s trichrome stain, 100x).  
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Figure 6-8: Diseased equine liver. Scoring system for equine hepatic disease, fibrosis score 
2.  There is non-bridging fibrosis within the hepatic parenchyma. (Masson’s trichrome stain, 
100x).  
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Figure 6-9: Diseased equine liver. Scoring system for equine hepatic disease, fibrosis score 
3.  There is extensive bridging fibrosis within the hepatic parenchyma. (Masson’s trichrome 
stain, 100x).  
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6.4 Results   
 
The kappa statistic determined that a moderate agreement was found between the two 
pathologists who independently examined all cases for each of the evaluated parameters, as 
interpreted according to Landis and Koch (Table 4-1).167 Inflammation was present in 81.8% of 
cases, and bile duct proliferation was present in 35.7% of cases. A positive correlation was 
observed between inflammation and fibrosis scores using Spearman’s Rank Test (Spearman’s 
rho = 0.4046, P = 0.003).54 No significant correlation was found between bile duct proliferation 
and inflammation or fibrosis. 
 
The expression of MT and Ki-67 in normal liver samples was low to absent in comparison to 
diseased livers (Figs 4-10 and 4-11, respectively). Metallothionein expression was observed 
within hepatocytes in 73 out of 77 (94.8%) cases of equine liver disease, with a median of 42.0 
positive cells and a range of 0 to 166.3 positive cells per 25 µm2. Both cytoplasmic and nuclear 
staining was observed. Metallothionein expression was also occasionally observed in bile duct 
epithelium and lymphocytes.  
 
Out of 77 cases, 8 (10.4%) had evidence of Ki-67 expression within hepatocyte nuclei (Fig. 4-
12), 10 (13%) had nuclear expression within bile duct epithelium (Fig. 4-13), and 42 (54.6%) 
displayed nuclear expression within Kupffer cells (Fig. 4-14). Nuclear staining was more 
prominent within bile duct epithelial cells than hepatocytes, where the pattern of expression was 
sparse and limited to individual random hepatocytes. Strong Ki-67 expression was found in all 
lymphocytic inflammatory foci (Fig. 4-14). 
 
Rhodanine staining for intracellular copper within hepatocytes was seen in 3 out of 10 cases of 
diseased liver. The distribution of positive rhodanine staining was random, sparse and observed 
only within individual or small aggregates of cells, predominantly in periportal areas (Fig. 4-15). 
The staining intensity within hepatocytes of normal liver samples was very weak to absent. 
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Metallothionein expression was significantly associated with Ki-67 staining in bile duct 
epithelium and Kupffer cells (Table 4-3). More specifically, median MT expression within 
hepatocytes was significantly increased when Ki-67 expression was observed within bile duct 
epithelium, in contrast to when it was absent (median 106.8 versus 33.0 cells/25 µm2, P = 
0.0004; Fig. 4-17). In addition, when MT expression was compared between the presence or 
absence of Ki-67 within sinusoidal Kupffer cells (Fig. 4-18), there was a significant increase in 
MT expression in the Ki-67 positive group (median MT expression of 74.6 versus 15.2 cells/25 
µm2, n = 77, P = 0.0045). Median MT expression was also higher in cases containing 
lymphocytic infiltrates compared to cases with no lymphocytic infiltrate (76.1 versus 25.75 
cells/25 µm2, P = 0.0017; Fig. 4-19). Strong Ki-67 expression was found in all lymphocytic 
inflammatory foci. 
 
No significant differences were observed in MT expression between positive and negative Ki-67 
hepatocyte groups (Fig. 4-20), and no association was found between MT expression and 
inflammation (Fig. 4-21), fibrosis (Fig. 4-22) and bile duct proliferation (Fig. 4-23). See also 
Table 4-2.  
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6.4.1 Results tables 
 
Table 6-1: Inter-observer agreement for two pathologists’ histologic scores of all 77 
diseased liver samples for hepatic inflammation, fibrosis and bile duct proliferation using 
the kappa statistic.   The kappa statistic is calculated from the observed and expected 
agreement, which is derived from the distribution of scores for each pathologist. A kappa of 1 
indicates perfect agreement, whereas a kappa of zero indicates agreement equivalent to that 
obtained by chance. A kappa score of 0.41 to 0.60 is interpreted as “moderate” agreement.167 The 
P–value represents the probability that the calculation of the kappa value is due to chance. 
 
 Observed 
agreement 
Expected 
agreement 
Kappa 
value 
P-value Interpretation 
Inflammation 66.23% 28.25% 0.529 < 0.0001 moderate 
      
Fibrosis 61.04% 32.92% 0.419 < 0.0001 moderate 
      
Bile Ducts 80.52% 54.01% 0.577 < 0.0001 moderate 
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Table 6-2: Summary table of median metallothionein expression (and interquartile range) 
for all 77 diseased equine livers for each categorized outcome variable and associated P-
value (for Dunn’s test with post-hoc Sidak adjustment). The median metallothionein 
expression is measured as the number of positive cells per 25 µm2. The interquartile range 
represents the middle 50% of values when ordered from lowest to highest. The P-value 
represents the probability that there is no difference in metallothionein expression by grade for 
inflammation, and fibrosis, as assessed by pathologist A and B. Total number of observations (n-
value) per grade for each category is given. 
 
 
 
 
 Metallothionein expression (number of positive 
cells per 25 µm2) per diseased liver and (interquartile range) 
 
Categorized Variables Grade P-value 
 0 1 2 3  
inflammation 
(pathologist A) 
59  
(22.6 - 112.1) 
n = 8 
29.8 
(2.4 - 77.6) 
n = 39 
60.3 
(15.0 - 97.3) 
n = 16 
74.6 
(41.6 - 93) 
n = 14 
0.1423 
inflammation 
(pathologist B) 
47.6 
(10.3 - 82.6) 
n = 20 
29.4 
(0.9 - 83.5) 
n = 27 
74.7 
(15.2 - 99.3) 
n = 21 
74.5 
(41.6 - 85.1) 
n = 9 
0.0956 
fibrosis 
(pathologist A) 
51.2 
(44 - 58.4) 
n = 5 
20.35 
(6 - 99.1) 
n = 8 
38.7 
(4.4 - 99.3) 
n = 31 
49.6 
(13.6 - 89.2) 
n = 33 
0.9822 
fibrosis 
(pathologist B) 
51.2 
(30.4 - 66.8) 
n = 7 
26.4 
(3.2 - 89.2) 
n = 13 
35.85 
(11 - 87.6) 
n = 34 
74.7 
(4.6 - 95.2) 
n = 23 
0.8166 
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Table 6-3: Summary table of median metallothionein expression (and interquartile range) 
for all 77 diseased equine livers for each dichotomized outcome variable and associated P-
value (for Mann-Whitney U-test). The median metallothionein expression is measured as the 
number of positive cells per 25 µm2. The interquartile range represents the middle 50% of 
metallothionein expression when ordered from lowest to highest. The P-value represents the 
probability that there is no difference in metallothionein expression by the presence or absence of 
bile duct proliferation (as assessed by pathologist A and pathologist B) as well as the presence or 
absence of Ki-67 expression within bile duct epithelium, lymphocytes, Kupffer cells, and 
hepatocytes (as assessed by a single observer). The total number of observations (n-value) is 
provided for each category. 
 
 Metallothionein expression (number positive 
cells/ 25 µm2) per diseased liver and 
(interquartile range) 
 
Dichotomized 
Variables 
Absent Present P-value 
bile duct 
proliferation 
(pathologist A) 
33  
(4.4 - 83.5) 
n = 51 
72.7 
(11 - 93.3) 
n = 26 
0.105 
bile duct 
proliferation 
(pathologist B) 
31.7 
(4.5 - 81.7) 
n = 48 
74.5 
(14.8 - 95.2) 
n = 29 
0.0895 
Ki-67 within bile 
duct epithelium 
33 
(4.6 - 79.9) 
n = 67 
106.8 
(95.2 - 117.5) 
n = 10 
0.0004 
Ki-67 within 
lymphocytes 
25.8 
(2.4 - 66.8) 
n = 38 
76.1 
(27.6 - 99.7) 
n = 39 
0.0017 
Ki-67 within 
Kupffer cells 
15.2 
(3.2 - 66.8) 
n = 35 
74.6 
(30.4 - 95.2) 
n = 42 
0.0045 
Ki-67 within 
hepatocytes 
40.7 
(9.6 - 87.6) 
n = 69 
74.35 
(47.5 - 104.5) 
n = 8 
0.1872 
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6.4.2 Results figures 
 
 
 
Figure 6-10: A representative image of immunohistochemistry for metallothionein within a 
histologically normal equine liver. Metallothionein immunoreactivity is absent to low within 
hepatocytes and staining is uniform (400x).    
83 
 
 
Figure 6-11: A representative image of high metallothionein immunoreactivity within 
hepatocytes in a section of diseased equine liver. Both cytoplasmic and nuclear staining is 
present (400x).   
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Figure 6-12: A representative image of a single hepatocyte with positive immunoreactivity 
for Ki-67 within its nucleus in a section of diseased equine liver. 1000x magnification. 
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Figure 6-13: A representative image of immunoreactivity for Ki-67 within the nuclei of bile 
duct epithelial cells and surrounding lymphocytes in diseased equine liver. 200x 
magnification.  
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Figure 6-14: A representative image of Ki-67 immunoreactivity within the nuclei of three 
Kupffer cells (located within sinusoids) in diseased equine liver. 1000x magnification.  
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Figure 6-15: A representative image of rhodanine staining (orange-red granules) for 
copper within the cytoplasm of periportal hepatocytes in diseased equine liver. 400x 
magnification. 
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Figure 6-16: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by the absence or presence of Ki-67 expression within bile duct 
epithelium of diseased equine liver. Metallothionein expression was measured as the mean 
number of positively expressing hepatocytes per 25 µm2 over 10 fields per liver section. The 
Mann-Whitney U- test demonstrated a significant difference in metallothionein expression 
within hepatocytes between diseased livers that demonstrated Ki-67 expression within bile duct 
epithelium in comparison to those diseased livers that did not (P = 0.0004) A box and whisker 
plot is interpreted as follows. The green box indicates the 25th and 75th percentile (lower and 
upper quartile, respectively; also known as the interquartile range), the green line within the box 
indicates the median of the data distribution. The upper and lower whiskers indicate the most 
extreme values within 1.5 times the interquartile range of the nearer quartile. The green dots 
outside the whiskers indicate the presence of outliers which are data values outside 1.5 times the 
interquartile range. The number of observations in each group is given as an n-value above the 
whisker.  
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Figure 6-17: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by the absence or presence of Ki-67 expression within Kupffer cells of 
diseased equine liver. Metallothionein expression was measured as the mean number of 
positively expressing hepatocytes per 25 µm2 over 10 fields per liver section. The Mann-
Whitney U- test demonstrated a significant difference in metallothionein expression within 
hepatocytes between diseased livers that demonstrated Ki-67 expression within Kupffer cells in 
comparison to those diseased livers that did not (P = 0.0045). A box and whisker plot is 
interpreted as follows. The green box indicates the 25th and 75th percentile (lower and upper 
quartile, respectively; also known as the interquartile range), the green line within the box 
indicates the median of the data distribution. The upper and lower whiskers indicate the most 
extreme values within 1.5 times the interquartile range of the nearer quartile. The number of 
observations in each group is given as an n-value above the whisker.  
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Figure 6-18: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by the absence or presence of lymphocytic foci within diseased equine 
liver. Metallothionein expression was measured as the mean number of positively expressing 
hepatocytes per 25 µm2 over 10 fields per liver section. The Mann-Whitney U- test demonstrated 
a significant difference in metallothionein expression within hepatocytes between diseased livers 
that demonstrated the presence of lymphocytic foci in comparison to those diseased livers that 
did not (P = 0.0017) A box and whisker plot is interpreted as follows. The green box indicates 
the 25th and 75th percentile (lower and upper quartile, respectively; also known as the 
interquartile range), the green line within the box indicates the median of the data distribution. 
The upper and lower whiskers indicate the most extreme values within 1.5 times the interquartile 
range of the nearer quartile. The green dot outside the whiskers indicates the presence of an 
outlier which is a data value outside 1.5 times the interquartile range. The number of 
observations in each group is given as an n-value above the whisker.  
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Figure 6-19: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by the absence or presence of Ki-67 expression within hepatocytes of 
diseased equine liver. Metallothionein expression was measured as the mean number of 
positively expressing hepatocytes per 25 µm2 over 10 fields per liver section. No significant 
difference in metallothionein expression within hepatocytes was found between diseased livers 
that demonstrated Ki-67 expression within hepatocytes compared to those that did not (Mann-
Whitney U-test, P = 0.1872). A box and whisker plot is interpreted as follows. The green box 
indicates the 25th and 75th percentile lower and upper quartile, respectively; also known as the 
interquartile range), the green line within the box indicates the median of the data distribution. 
The upper and lower whiskers indicate the most extreme values within 1.5 times the interquartile 
range of the nearer quartile. The number of observations in each group is given as an n-value 
above the whisker.  
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Figure 6-20: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by inflammation score as assessed by pathologist A and pathologist B 
for diseased equine liver. Metallothionein expression was measured as the mean number of 
positively expressing hepatocytes per 25 µm2 over 10 fields per liver section. The Dunn’s test 
with a post-hoc Sidak adjustment (to account for multiple comparisons) did not demonstrate any 
significant differences in metallothionein expression within hepatocytes between groups of 
different inflammation scores for neither pathologist A or B (P = 0.1423 and P = 0.0955, 
respectively). A box and whisker plot is interpreted as follows. The green box indicates the 25th 
and 75th percentile (lower and upper quartile, respectively; also known as the interquartile range), 
the green line within the box indicates the median of the data distribution. The upper and lower 
whiskers indicate the most extreme values within 1.5 times the interquartile range of the nearer 
quartile. The number of observations in each group is given as an n-value above the whisker.  
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Figure 6-21: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by fibrosis score as assessed by pathologist A and pathologist B for 
diseased equine liver. Metallothionein expression was measured as the mean number of 
positively expressing hepatocytes per 25 µm2 over 10 fields per liver section. The Dunn’s test 
with a post-hoc Sidak adjustment (to account for multiple comparisons) did not demonstrate any 
significant differences in metallothionein expression within hepatocytes between groups of 
different fibrosis scores for either pathologist A or B (P = 0.9822 and P = 0.8166, respectively). 
A box and whisker plot is interpreted as follows. The green box indicates the 25th and 75th 
percentile (lower and upper quartile, respectively; also known as the interquartile range), the 
green line within the box indicates the median of the data distribution. The upper and lower 
whiskers indicate the most extreme values within 1.5 times the interquartile range of the nearer 
quartile. The number of observations in each group is given as an n-value above the whisker.  
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Figure 6-22: Box and whisker plot detailing the distribution of metallothionein expression 
within hepatocytes by the absence or presence of bile duct proliferation as assessed by 
pathologist A and pathologist B within diseased equine liver. Metallothionein expression was 
measured as the mean number of positively expressing hepatocytes per 25 µm2 over 10 fields per 
liver section. Cases with greater than four bile ducts per field were considered to have bile duct 
proliferation, whereas cases with zero to four bile ducts per field were regarded as not 
proliferated. The cut-off value of four bile ducts per field was determined by utilizing the bile 
duct counts of six histologically normal liver sections (ten random fields per section) measured 
by both pathologists. Four or fewer bile ducts per field were found in 95% of the 60 counted 
fields. No significant difference in metallothionein expression within hepatocytes was found 
between diseased livers that demonstrated bile duct proliferation compared to those that did not 
for neither pathologist A nor pathologist B (Mann-Whitney U-test, P = 0.1050 and P = 0.0895, 
respectively). A box and whisker plot is interpreted as follows. The green box indicates the 25th 
and 75th percentile (lower and upper quartile, respectively; also known as the interquartile range), 
the green line within the box indicates the median of the data distribution. The upper and lower 
whiskers indicate the most extreme values within 1.5 times the interquartile range of the nearer 
quartile. The number of observations in each group is given as an n-value above the whisker.  
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6.5 Discussion 
 
The objective of the current study was to evaluate the role of MT in chronic equine hepatic 
disease by correlating its expression within hepatocytes with common pathologic lesions seen in 
the diseased liver, and with cellular proliferation in different cell types within the liver. We 
report for the first time the presence of a significant relationship between elevated MT 
expression within hepatocytes and the presence of lymphocytic inflammation or Ki-67 
immunostaining within bile duct epithelium and Kupffer cells.  
 
Metallothionein is known to play a role in mediating inflammation,133 and its gene expression 
can be induced by cytokines, glucocorticoids, and oxidative stress.198 Although primarily 
localized intracellularly within many cell types, MT has also been found extra-cellularly within 
biological fluids including serum, urine, and milk.10,193,204,272,280 Interestingly, extracellular MT 
has been shown to be involved in leukocyte chemotaxis, proliferation, and activation. For 
example, Yin et al. reported that inflammatory cells migrate towards an increasing MT gradient, 
a response which can be specifically blocked by antibodies targeting MT.313 Additionally, MT 
has been shown to induce the proliferation of B cells and enhance their capacity to differentiate 
into plasma cells.27,175 In our study, hepatic MT expression was elevated when Ki-67 was present 
within lymphocytes. It is, therefore, plausible that MT produced by hepatocytes promotes 
lymphocyte proliferation in chronic liver disease in horses. Another possibility is that 
lymphocytic inflammation drives hepatic MT expression.  
 
The significant positive relationship between the presence of Ki-67 immunoreactivity within 
sinusoidal Kupffer cells and increased MT within hepatocytes further supports the role of MT as 
an inflammatory mediator in equine liver disease. Intra-sinusoidal Kupffer cells play a major role 
in the first line of defense against toxic and infectious agents within the liver, both acute and 
chronic, and activation of these cells causes a release of cytokines, interleukins, and reactive 
oxygen species.1,307 Kupffer cells may contribute to hepatocellular injury,137,168 or may be 
protective against it,145 as in the case of acetaminophen toxicity. Additionally, acetaminophen 
alone had only a minimal effect on Kupffer cells chemotaxis and phagocytosis, suggesting 
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factors released from hepatocytes themselves may modulate Kupffer cell activation.168 In a 
thioacetamide-induced liver injury study by Andres et. al., pre-treatment of rat liver with 
gadolinium chloride prior to thioacetamide selectively inactivated Kupffer cells, enhanced 
hepatic MT expression and decreased the overall hepatotoxic effect of thioacetamide in rats.8 In 
our study, Ki-67 expression was observed within Kupffer cells, suggesting that these resident 
macrophages are actively engaged in the cell cycle. It is possible, therefore, that MT produced by 
hepatocytes modulated the activation of Kupffer cells.  
 
This study also showed that MT might play a role in mitosis of bile duct epithelia in horses, as 
increased MT expression within hepatocytes was observed when Ki-67 immunostaining was 
present within bile duct epithelium. Although bile duct proliferation was not significantly 
associated with MT expression, an increasing trend was observed (Figure 4-23), and non-
significance may reflect limited statistical power in this study. MT may play a role in cellular 
regeneration by regulating the pool of available zinc, which is essential for cell growth and 
division.47 
 
Liver regeneration occurs either by the proliferation of mature hepatocytes, by ductular reaction, 
or both. Ductular reaction originates from bipotent hepatic progenitor cells (HPCs) within 
hepatic portal areas and represents an array of reaction patterns depending on the types and 
severity of hepatic injury.112 Unexpectedly, very little Ki-67 immunostaining was observed in 
hepatocytes, despite achieving appropriate levels of immunostaining in each positive control 
sample. In a previous study, MT was assessed in the diseased canine liver, and Ki-67 expression 
within hepatocytes ranged from 0.4 to 25.2%.262 It is plausible that a species-specific pattern of 
regeneration exists. It is also possible that Ki-67 was absent because these cells reached the 
resting phase of the cell cycle and were no longer dividing. Alternatively, hepatocyte 
regeneration may be accomplished less conventionally. For example, in a 30% partial 
hepatectomy (PHx) mouse model of liver regeneration, regeneration was achieved solely by cell 
hypertrophy without cell division.196 In the same study, whereby a 70% PHx occurred, liver 
regeneration was achieved mainly by cell hypertrophy prior to proliferation. Most cells entered 
S-phase of the cell cycle, but not all cells progressed to M-phase, whereby liver regeneration was 
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a result of near equal contributions of hepatocellular hypertrophy and proliferation.196 However, 
MT staining was observed within the nuclei of hepatocytes in the current study, suggesting that 
hepatocytes were regenerating as MT immunostaining within the nucleus is associated with 
hepatocyte proliferation.47,280,285 Kupffer cells may also influence differentiation, but not the 
proliferation, of HPCs during liver injury in mice.291 Therefore, hepatocyte regeneration in 
horses may progress by alternative mechanisms, or is significantly slower, and may be achieved 
by an equal contribution from hepatocytes and bile duct epithelia.   
 
Rhodanine staining for copper was absent in normal liver samples as well as in seven out of ten 
cases of diseased liver. Only sporadic staining was observed in the remaining three cases. All ten 
sections of diseased liver submitted for rhodanine staining had elevated levels of MT 
immunostaining. It is known that MT gene transcription can be induced by the presence of heavy 
metals such as cadmium, copper, and zinc, 119,155 therefore an investigation into a possible link 
between copper and elevated MT expression in the equine liver was carried out. Based on the 
paucity of rhodanine staining, it is likely that copper does not play a role in chronic hepatic 
disease in horses. Furthermore, there is no obvious connection between copper and MT 
expression in the equine liver in this study, although this would need to be investigated further 
with more samples to be definitive. There is only a limited amount of information on hepatic 
copper levels in horses, though they are relatively resistant to toxicosis.257 Rare reports do exist 
of copper causing acute hepatic disease.12 Additional studies are needed to elucidate the role of 
copper in the development and progression of liver disease in horses.  
 
Agreement between pathologists was moderate, with the degree of fibrosis being the most 
difficult lesion to agree upon, despite being provided a rigorous scoring guideline prior to liver 
section evaluation. Indeed, despite the study inclusion criteria that histologic sections required at 
least a minimum of hepatic fibrosis, and this was assessed by two pathologists prior to the study, 
both pathologist A and pathologist B still scored five and seven sections as having 0 fibrosis, 
respectively. The scoring of histologic sections contains a subjective element and will always 
have some degree of observer variability. In human medical studies, Cohen’s kappa statistic is 
often used to determine the degree of inter-rater agreement (0=no agreement, 1=perfect 
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agreement). In general, Kappa values in this study were consistent with other studies involving 
scoring systems for chronic liver disease.129 
 
In conclusion, MT appears to have a role in chronic hepatic lesions in horses, potentially 
mediated through lymphocytic inflammation and Kupffer cells. Based on these study results, one 
cannot determine the directionality of this relationship. Metallothionein may potentiate the 
inflammatory response, or, the inflammatory response may induce or enhance the expression of 
MT. Furthermore, MT expression may be related to cell proliferation of bile duct epithelial cells, 
which in turn, may contribute significantly to the regeneration of the equine liver in chronic 
disease.  
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CHAPTER 7: SUMMARY AND GENERAL DISCUSSION 
 
The aim of the studies presented in this thesis was to evaluate the potential role of 
metallothionein (MT) in chronic liver disease in equids, independent of the cause or etiology. 
Also, a retrospective study was performed to evaluate the types and frequency of hepatic 
histopathologic lesions from equids of all life stages, including fetuses, and to compare what is 
observed in this regional population to what is known in the literature as a whole.  
 
The impetus for this research started with a similar MT project within our research group, in 
canine chronic hepatic disease.262 In that study, a statistically significant positive correlation 
between MT expression and cellular regeneration (growth fraction) and a  negative correlation 
between hepatic MT expression and fibrosis was observed. In the large body of research 
involving human hepatic disease, including rodent models, MT has been implicated in numerous 
inflammatory processes, hepatic fibrosis, as well as cellular regeneration and neoplasia. There is 
no current literature about the involvement of  MT with biliary hyperplasia, though its 
overexpression has been observed in human cholangiocarcinoma.245 
 
The study I presented in this thesis demonstrated that MT, assessed by immunohistochemistry 
(IHC), plays a role in chronic hepatic disease in equids. MT was shown to be associated with 
inflammatory processes in the equine liver, potentially mediated through lymphocytic 
inflammation and Kupffer cells. In addition, it was shown to be associated with biliary epithelial 
regeneration by Ki-67 expression. As this was the first attempt at assessing hepatic MT by IHC 
in horses, an equine hepatic MT protocol needed to be developed and validated for this project. 
When it came time to assess Ki-67 expression, also by IHC, it was very surprising how little was 
being expressed by hepatocytes, especially when compared to the canine study performed 
previously. The significance of this finding is unclear, although it is possible that hepatic 
regenerative mechanisms vary between differing species. The small sample size in each 
histopathologic score was a limitation to this study and limited the study’s power and level of 
sensitivity.  
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In conclusion, these findings strongly suggest that MT is involved in chronic hepatic lesions and 
regeneration in horses. The direction of this relationship during inflammation, however, is still 
under question. It is known that inflammation can induce the expression of MT, specifically 
through interleukin-6,155 and yet it has also been shown that elevated MT levels can change 
cytokine levels produced by various immune cells.13 Also, it is unclear if MT works as an anti-
inflammatory in this regard, as is most often cited in the literature, or if it acts in a pro-
inflammatory manner. This is also the first known account of a possible relationship between 
MT and the regeneration of biliary epithelial cells. Strong evidence in the literature supports a 
role for MT in promoting cellular regeneration, especially in the liver. Unlike what was observed 
in the canine study in which no Ki-67 expression was observed within biliary epithelial cells,262 
Ki-67 expression was observed in equine biliary epithelium, and this was significantly associated 
with MT expression. This suggests a species-specific mechanism for hepatic regeneration and 
variability in the role of MT in hepatic regeneration.  
 
The results of the 20-year retrospective analysis are in alignment with what is known from the 
literature. This suggests that the population in the study shared many similarities with the equine 
population in general, with respect to hepatic disease, and that the results of the MT study may 
be applied to the equine population as a whole. Quarter Horses were by far the most represented 
breed. The most commonly diagnosed hepatic lesions were: suppurative to mixed hepatitis, 
multi-focal hepatocellular necrosis, and portal fibrosis with bile duct proliferation. All these 
lesion categories were significantly associated with life stage, suggesting that there is a 
susceptibility to certain disease entities at distinct stages of development. Not surprisingly, 
breeds such as donkeys, ponies, and Miniature Horses were significantly associated with 
hepatocellular vacuolation. What was surprising, however, was the overall increasing trend of 
suppurative to mixed hepatitis across the study years. Bacterial hepatitis likely is a compelling 
cause of suppurative hepatitis in equids. However, very few samples overall were submitted for 
bacterial culture.  
 
Based on these findings, the following recommendations are suggested. Due to the increasing 
trend of suppurative hepatitis, it is advisable to submit (fresh) samples of liver whenever possible 
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for bacterial culture. In addition, biopsy is able to detect the majority of lesions in the equine 
liver. Taken together with any ancillary testing, such as ultrasonography and bloodwork, it can 
provide valuable information that can guide the practitioner in providing a prognosis or in 
determining a possible etiology.   
 
As the clinical signs of equine liver disease are vague and only occur once disease has 
progressed significantly, the development of a rapid and cost-effective screening test for hepatic 
disease would be incredibly useful to practitioners. Immunohistochemistry is an excellent 
visualization tool, but quantitative real-time PCR (qRT-PCR) is a much more sensitive detection 
method. Metallothionein has been accurately detected by qRT-PCR from blood samples 
determined from dried blood spots on filter paper.13 If one were able to correlate peripheral blood 
MT levels with various states of hepatic disease, such as might be accomplished through 
prospective disease studies, an animal-side or rapid test could be developed. However, caution is 
warranted as aberrant MT expression has also been observed in other organs and disease 
processes including Alzheimer’s disease,169 as well as various neoplastic processes.114A 
screening test may also be a useful indicator for performing a liver biopsy. 
 
Another possible application of the results of these studies may involve the development of a 
histologic scoring system for hepatic biopsies. The scoring system developed in this study could 
be applied to prospective disease studies and correlated to clinicopathologic findings, survival 
curves, and etiologies. In this way, biopsy submissions could be evaluated for inflammation, 
fibrosis, bile duct proliferation in addition to MT expression which may aid in prognosis and 
therapeutic intervention. For example, it would be interesting to evaluate MT expression with 
biopsy scores of biliary hyperplasia and fibrosis and clinical outcome. In this way, important 
prognostic information can be determined in potential cases of chronic toxin exposure, especially 
since no etiologic agent can be definitively identified. 
 
The role of MT in equine neoplastic processes could also be assessed, and is not limited to 
hepatic neoplasia, but other organ systems as well. The IHC protocol developed in this study 
could be applied to other equine tissues.  
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This is an exciting area of research, with many possible applications to human and animal 
disease diagnosis and treatment. 
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